GLOBAL P4P. Pay for Performance (P4P) Program Guide

Size: px
Start display at page:

Download "GLOBAL P4P. Pay for Performance (P4P) Program Guide"

Transcription

1 GLOBAL P4P Pay for Performance (P4P) Program Guide Contact: Published: January 10, 2018

2 PROGRAM OVERVIEW IEHP is pleased to provide an update for the Global Quality Pay for Performance (GQ P4P) Program for IPAs in In this third year of the program, IEHP has made program enhancements based on feedback from Providers and in an effort to continually improve effectiveness. The IEHP GQ P4P Independent Physician Associations (IPAs) was designed to reward IPAs for high performance and year-over-year improvement in key quality performance measures. This program overview is designed for IPAs and their staff as an easy guide to help maximize GQ P4P. In its third year, the GQ P4P Program is an expansion of IEHP s 2017 GQ P4P Program and provides financial rewards to IPAs for improving healthcare quality across multiple domains and measures. The 2018 GQ P4P program focuses on performance-based incentives to IPAs for services rendered in 2018 and will be provided to IPAs for high performance and for year-overyear improvement. If you would like to get more information about IEHP s GQ P4P Program or best practices to help improve quality scores and outcomes, visit our Secure Provider Portal at the Quality Team at QualityPrograms@iehp.org or call the IEHP Provider Relations Team at What s New? Two (2) measures retired Annual Monitoring for Patients on Persistent Medications - Total Childhood Immunizations - Combo 3 Three (3) measures added to the Clinical Quality Domain Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents Concurrent Use of Opioids and Benzodiazepines (monitoring only) New Tier 1 and Tier 2 goal methodology to include a practical significance standard Budget reduced from $30 million to $20 million, with removal of the condition to pass through 33%-50% of the funding to PCPs that was in place for previous program years 1

3 Eligibility and Participation To be eligible for incentive payments in the 2018 GQ P4P Program, IPAs must meet the following criteria: Have at least 5,000 IEHP Medi-Cal Members assigned as of January 2018 Have at least 30 Members in the denominator as of December 2018 for each quality measure to qualify Submit a GQ P4P Quality Work Plan to IEHP by March 1, 2018 in order to enroll in the program (see Work Plan details in Appendix 5) Meet minimum Encounter Data Gates in order to qualify for incentive payments Minimum Data Requirements Encounter Data Encounter data is foundational to performance scoring and is essential to success in the GQ P4P Program. Complete, timely and accurate encounter data should be submitted through normal reporting channels for all services rendered to IEHP Members. Please reference the codes listed in Appendix 2 to help with proper coding to meet measure requirements. Lab Results Lab results data is also foundational to performance scoring in the Program. Providers should ensure submission of complete lab results data for services rendered to IEHP Members. IPAs should work with their network providers to ensure the appropriate lab vendors are used for IEHP Members and lab results data are being sent to IEHP. Lab results that are performed in the office (e.g., point of care HbA1c testing, urine tests, etc.) should be coded and submitted through providers encounter data. Immunizations To maximize performance in immunization-based measures, IEHP strongly encourages all Providers to report all immunizations via the California Immunization Registry (CAIR2). For more information on how to register for CAIR2, please visit IEHP is working closely with CAIR in establishing a data sharing arrangement to be used in Global Quality P4P reporting. 2

4 Supplemental Data What is Supplemental Data? When services are not captured in traditional encounter data systems, other supplemental data sources may be used to collect information about services rendered to Members to support Quality Reporting. When Supplemental Data may be needed? Typically for services that occurred in the past (prior to eligibility) When provider has proof-of-service for a noted gap in care (e.g. cervical cancer screening, immunizations rendered by another provider) When provider has proof-of-service for an eligible-population exclusion (e.g. total hysterectomy, bilateral mastectomy) How to use supplemental data to support Global Quality P4P? Create an electronic log that includes minimum required data elements. See Appendix 6 for file layout requirements. Below is a listing of minimum data elements needed in a supplemental data log. Member ID Date of Service Provider Identification Provider Specialty Diagnosis Code(s) if applicable Procedure Code(s) Lab Results (if applicable) Requirements for use of Supplemental Data in Global Quality P4P Reporting IPA must have clearly defined policies and procedures (in writing) that describe how this data is collected, validated and used for P4P reporting Policy/Procedure must be shared with IEHP and must be in place to validate quality / accuracy of supplemental data IPA must collect Proof of Service documentation to confirm all services reported in Supplemental Data log Must receive approval from IEHP s Quality Team for use in Global Quality Reporting (Deadline for approval is 10/31/2018) IPA must complete P4P Roadmap no later than 12/1/2018 IPA must complete IPA data validation activities prior to submitting data to IEHP IPA must submit final supplemental data log to IEHP via SFTP no later than February 1,

5 Data Validation Requirements for Supplemental Data in Global Quality P4P Reporting In order to be counted in final IPA Global Quality P4P rates, supplemental data file must pass IEHP s independent HEDIS audit process IPA must present proof-of-service documents when requested by IEHP s auditors within required timeframes Auditor review will compare proof of service document to submitted data Supplemental data records must pass 100% validation in order to be included in final P4P reporting Financial Overview Providers are eligible to receive financial rewards for performance excellence and for performance improvement. Financial rewards are based on a tiered system, providing increasing financial rewards for reaching higher tiered level performance. The 2018 GQ P4P Program incentive pool is $20 million for the IPA program. Incentive dollars for the 2018 performance period are scheduled to be made in January 2019 (interim) and July 2019 (final). IPA Encounter Data Gates IPA encounter data submissions must meet minimum adequacy requirements in order to receive GQ P4P Program incentive dollars. IPA encounter data performance is based on all professional encounters submitted by the IPA for services rendered during the measurement year (i.e dates of service). IPA encounter data volume will be compared to established encounter data benchmarks for SPD and Non-SPD membership. IPA performance will be calculated against each IPA s proportion of SPD and Non-SPD membership. Encounter data benchmarks have been established and correspond to an encounter data gate, reflecting higher encounter data volumes. As IPAs reach higher levels of encounter data performance, they become eligible for a larger percentage of the total possible GQ P4P incentive. Encounter rates are expressed as the number of encounters per Member per year (PMPY). An encounter is defined as a unique visit per Member per Provider per day. Below is a table describing the Encounter Data Gates, performance levels, and their impact to IPA GQ P4P Program incentive payments. % OF POSSIBLE INCENTIVE PAYMENT ENCOUNTER DATA GATE NON-SPD PMPY SPD PMPY 50% Gate % Gate % Gate

6 Encounter data gating methodology only applies to the IPA methodology. Encounter data must be submitted to IEHP timely and adhering to reporting timeframes established in IEHP s Provider Policy and Procedure Manual - Policy 21A. Performance Measures Appendix 1 provides a list of the twenty-two (22) measures included in the 2018 GQ P4P Program including thresholds and benchmarks associated with respective tier goals. These measures have been categorized into 4 domains: Clinical Quality; Behavioral Health Integration; Patient Experience; Encounter Data. Most measures included in the Clinical Quality Domain primarily uses standard Healthcare Effectiveness Data and Information Set (HEDIS ) process and outcomes measures based on the specifications published by the National Committee for Quality Assurance (NCQA). Non-HEDIS measures included in the Clinical Quality domain come from the Department of Healthcare Services (DHCS) Medi-Cal Managed Care Quality Program and the Pharmacy Quality Alliance (PQA). Clinical Quality Measures: Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (New) Breast Cancer Childhood Immunizations Combo 10 Comprehensive Diabetes Care Eye Exam Comprehensive Diabetes Care HbA1c Control < 8 Concurrent Use of Opioids and Benzodiazepines (New) Immunizations for Adolescents Combo 2 Initial Health Assessment Medication Management for People with Asthma 75% rate Timely Postpartum Care Timely Prenatal Care Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents (New) - Counseling for Physical Activity - Counseling for Nutrition - BMI Percentile IEHP s HEDIS 2019 data set (measurement year 2018) will be used to evaluate Providers year-end performance. This measure set undergoes an independent audit review prior to rate finalization. 5

7 The Initial Health Assessment measure follows IEHP s IHA internal compliance monitoring methodology and is not a HEDIS measure. The Concurrent Use of Opioids and Benzodiazepines measure specification is developed and maintained by the Pharmacy Quality Alliance (PQA). This measure will not be used for incentive calculations but will be collected to establish a baseline rate for See Appendix 2 listed in this program guide for measure details. Behavioral Health Integration Domain Measures: Measures included in the Behavioral Health Integration Domain include two (2) measures derived from the Centers for Medicare and Medicaid Services (CMS) Physician Quality Reporting System (PQRS) measure set.1 for Clinical Positive Depression with Follow-Up Plan Patient Experience Domain Measures: Measures included in the Patient Experience Domain include Member Satisfaction Survey questions that are included in the Consumer Assessment of Healthcare Providers and Systems (CAHPS) survey published by the Agency for Healthcare Research and Quality (AHRQ). IEHP fields a Member Satisfaction Survey that is a modified CAHPS survey and is the sole data source supporting the performance scoring methodology for this measure domain. The IEHP Member Satisfaction Survey is fielded between June and December of each year. Surveys received from the 2018 Member Satisfaction Survey will be used to calculate the Patient Experience domain measures. A copy of the current Member Satisfaction Survey is available in Appendix 4 listed in this program guide. Access to Care Needed Right Away Access to Routine Care Coordination of Care Encounter Data Domain Measures: The fourth measure domain is Encounter Data. IPAs eligible for the GQ P4P Program become eligible for receiving payment dollars once meeting the minimum encounter data gate. Reaching higher encounter gate performance qualifies an IPA to receive a higher percentage of incentive dollars. See the IPA Encounter Data Gates section listed in this program guide for additional details on this methodology. 1 For information on the PQRS measure set: Assessment-Instruments/PQRS/index.html 6

8 2018 IPA Global Quality P4P Scoring and Payment Flowchart PROGRAM ELIGIBILITY REQUIREMENTS Membership will be determined as of 01/2018 IPAs with 5,000 or more assigned Members SCORING METHOD Incentive eligible IPAs will receive a Quality Score for each Measure IPAs must have 30 or more Members in each Measure to be eligible for a Quality Score The Quality Score is averaged to determine the Global Quality Performance Score At least three Measures are required to determine the Global Quality Performance Score IPA PAYMENT CALCULATION [Global Quality Performance Score] X [# Medi-Cal Average Member Months] = Member Points [Member Points] X [Payment Amount per Member Point] = Max Payment Amount [Max Payment Amount] X [Encounter Gate] = Final Payment Amount 7

9 Scoring Methodology Payment will be awarded to IPAs based on individual performance for reaching established Quality Goals (i.e., Tier Goals for each measure). In the Clinical Quality Domain, HEDIS measure results are based on each measure s total eligible population assigned to the IPA. The eligible population is defined as the set of Members that meet the denominator criteria specified in the current year HEDIS Technical Specifications (Volume 2) published by NCQA. Members in the eligible population are attributed to the assigned PCP on each measure s anchor date, as defined within the HEDIS measure. Members contribute to a IPA s HEDIS measure denominator if continuous enrollment criteria are met at the health plan level. For each measure, the HEDIS score reflects the proportion of the eligible population that is in compliance with the numerator criteria, as defined in the current HEDIS technical specifications (Volume 2). In the Clinical Quality Domain, non-hedis measure (i.e., Initial Health Assessment) results are based on new health plan Members assigned to the IPA during the measurement year and who remain enrolled with the Plan and the IPA through the 120 day post enrollment period. See Appendix 2 listed in this program guide for measure details. In the Patient Experience Domain, monthly Member satisfaction survey measures are based on Members who meet eligibility criteria to receive a mailed survey between June and December of the measurement year. Members eligible for receiving a Member Satisfaction Survey must have met continuous enrollment with IEHP for at least 6 months in the measurement year (2018) and must have an office visit in the prior 6 months based on encounter data submitted to IEHP. Members who meet the survey eligibility criteria are randomly sampled to receive a survey. Survey measure results are attributed to the Member s assigned IPA on the most recent encounter that qualified the Member to be eligible for the survey. A Member is eligible to receive only one survey per calendar year. For IPAs, the Encounter Data Domain measures assess the volume of IPA encounters received for all assigned IPA Members. The denominator is all assigned Medi-Cal Members each month of the measurement year (2018). All monthly assigned Members are summed to create the denominator (i.e., member months). The numerator is the sum of all unique encounters (i.e., unique Member, Provider, date of service) in the measurement year for all assigned Members in the denominator. A Per Member Per Year (PMPY) rate is calculated following this formula: Total Unique Encounters / Total Member Months x 12 = PMPY 8

10 Payment Methodology IPA performance on each quality measure will be given a point value (i.e., a Quality Score). Points are assigned based on the tier goal achieved (i.e. tier 1 = 1 point, tier 2 = 2 points, tier 3 = 3 points) for each measure. IPAs who have at least three (3) quality measures that meet the minimum denominator size (n = 30) will be considered for payment calculations. An average of all eligible Quality Scores will determine the overall GQ Performance Score. GQ P4P Program payments will be awarded according to the following formula: [Global Quality Performance Score] X [# Medi-Cal Average Member Months] = Member Points [Member Points] X [Payment Amount per Member Point] = Incentive Payout Total The payment amount per member point is dependent on the total incentive money available for IPAs. Using the formula below, the payment amount per member point is calculated as follows: MAX GLOBAL QUALITY PERFORMANCE SCORE PROVIDER # MEDI-CAL AVERAGE MEMBER MONTHS TOTAL* MEMBER POINTS 3 x 700,000 = 2,100,000 * This calculation is for illustration purposes only. TOTAL INCENTIVE DOLLARS AVAILABLE MEMBER POINTS PAYMENT PER MEMBER POINT** IPA $20,000,000 2,100,000 = $9.52 ** Final payment per Member point value will be finalized in the Spring of Figures above are for illustration purposes only. Rates will be shared with IPAs at least quarterly to track progress toward goals. Initial IPA reports will be available in March

11 Quality Incentive Payout Timeline: Provider Communication Timeline Interim 2017 GQ P4P payment (PCP & IPA) Final 2017 GQ P4P payment (PCP & IPA) Jan 2018 Feb 2018 Mar 2018 Apr 2018 May 2018 Jun 2018 Jul 2018 Aug 2018 Sep 2018 Oct 2018 Nov 2018 Dec 2018 End of Traditional PCP P4P Program Monthly Quality PMPM payments based on 2017 GQ P4P Performance year results (PCP only) Monthly Quality PMPM payments based on 2017 GQ P4P Performance year results (PCP only) Jan 2019 Feb 2019 Mar 2019 Apr 2019 May 2019 Jun 2019 Jul 2019 Aug 2019 Sep 2019 Oct 2019 Nov 2019 Dec 2019 Getting Help Monthly Quality PMPM payments based on 2018 GQ P4P Performance year results (PCP & IPA) Please direct questions and/or comments related to this program to IEHP s Provider Call Center at or to IEHP s Quality Department at QualityPrograms@iehp.org. Program Terms and Conditions Participation in IEHP s GQ P4P Program, as well as acceptance of incentive payments, does not in any way modify or supersede any terms or conditions of any agreement between IEHP and Providers or IPAs, whether that agreement is entered into, prior to or subsequent to, the date of this communication. There is no guarantee of future funding for, or payment under, any IEHP Provider incentive program. The IEHP GQ P4P Program and/or its terms and conditions may be modified or terminated at any time, with or without notice, at IEHP s sole discretion. Criteria for calculating incentive payments are subject to change at any time, with or without notice, at IEHP s sole discretion. In consideration of IEHP s offering of the IEHP GQ P4P Program, participants agree to fully and forever release and discharge IEHP from any and all claims, demands, causes of action, and suits, of any nature, pertaining to or arising from the offering by IEHP of the IEHP GQ P4P Program. The determination of IEHP regarding performance scoring and payments under the IEHP GQ P4P Program is final. As a condition of receiving payment under the IEHP GQ P4P Program, Providers and IPAs must be active and contracted with IEHP and have active assigned Members at the time of payment. 10

12 APPENDIX 1: 2018 IPA Global Quality P4P Program Measures 2018 GQ P4P PROGRAM MEASURE LIST Domain Measure Name Population Tier 1 Tier 2 Tier 3 Clinical Quality Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis 1 Adult 39.0% Improvement Improvement Clinical Quality Comprehensive Diabetes Care - HbA1c demonstrated demonstrated Control <8 Adult 58.0% by meeting the by meeting the Clinical Quality Comprehensive Diabetes Care - following following Eye Exam Adult 2 conditions: 2 conditions: 68.0% Clinical Quality Medication Management for People 10% 20% with Asthma - 75% Adult reduction reduction 48.0% Behavioral Health for Clinical Depression Adult and in noncomplianccompliance in non- Integration in Primary Care Adolescent 50.00% Behavioral Health Integration Positive Depression with Follow-Up Plan Adult and Adolescent AND AND 90.00% Clinical Quality Breast Cancer Women Improvement Improvement 71.0% of at least 2.0 of at least 3.0 Clinical Quality Women percentage percentage 70.0% Clinical Quality Timeliness of Prenatal Care Women points points 91.0% Clinical Quality Postpartum Care Women 74.0% Clinical Quality Childhood Immunizations - Combo 10 Child 46.0% Improvement Improvement Clinical Quality Immunizations for Adolescents - Combo 2 Child demonstrated demonstrated 32.30% by meeting by meeting Clinical Quality Well-Child Visits 3-6 Child the following the following 83.0% 2 conditions: 2 conditions: Clinical Quality Clinical Quality Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents - Counseling for Physical Activity 1 Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents - Counseling for Nutrition 1 1 New Measure for 2018 ** Reporting Only Measure. Not eligible for incentive dollars *** Encounter Data measure benchmarks are gates not tiers Child Child 10% reduction in noncompliance AND 20% reduction in noncompliance AND 72.0% 80.0% Weight Assessment and Counseling Improvement Improvement Clinical Quality for Nutrition and Physical Activity of at least 2.0 of at least 3.0 for Children and Adolescents - BMI Child 86.0% percentage percentage Percentile 1 points points Clinical Quality Initial Health Assessment All 50.00% Clinical Quality Concurrent Use of Opioids and Benzodiazepines 1 ** All Baseline Reporting Year Patient Experience Patient Experience Patient Experience Member Satisfaction Survey - Access to Care Needed Right Away Member Satisfaction Survey - Coordination of Care Member Satisfaction Survey Access to Routine Care All 84.00% 86.00% 88.00% All 82.00% 84.00% 86.00% All 82.00% 85.00% 86.00% Encounter Data Encounter Data for PCPs PMPY SPD*** All Encounter Data Encounter Data for PCPs PMPY - Non- SPD*** All

13 APPENDIX 2: Measures Overview Population: Adult Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis (AAB) Methodology: HEDIS Measure Description: The percentage of adults years of age with a diagnosis of acute bronchitis who were not dispensed an antibiotic prescription on or three days after the Index Episode Start Date (IESD). Episode Date is the date of service for any outpatient or ED visit during the Intake Period (1/1/ /24/18) with a diagnosis of acute bronchitis. IESD: the earliest Episode Date during the Intake Period with a diagnosis of acute bronchitis that meets all of the following criteria: 1. Episode Date is the date of service for any outpatient or ED visit during the Intake Period with a diagnosis of acute bronchitis. 2. A 30-day Negative Medication History prior to the Episode Date. 3. A 12-month Negative Comorbid Condition History prior to and including the Episode Date. 4. A Negative Competing Diagnosis during the 38-day period from 30 days prior to the Episode Date through 7 days after the Episode Date. 5. The member was continuously enrolled 1 year prior to the Episode Date through 7 days after the Episode Date. The measure is reported as an inverted rate [1 (numerator/eligible population)]. A higher rate indicates appropriate treatment of adults with acute bronchitis (i.e., the proportion for whom antibiotics were not prescribed). Members in hospice are excluded from the eligible population. Exclude denied claims when assessing numerator criteria. Do not include ED visits or observation visits that result in an inpatient stay. When an ED or observation visit and an inpatient stay are billed on separate claims, the visit results in an inpatient stay when the admission date for the inpatient stay occurs on the ED/ observation date of service or one calendar day after. An ED or observation visit billed on the same claim as an inpatient stay is considered a visit that resulted in an inpatient stay. 12

14 Denominator: Members years of age, who had an outpatient visit, an observation visit or an ED visit between January 1 December 24 of the measurement year (2018) with a diagnosis of acute bronchitis. Numerator: Dispensed prescription for an antibiotic medication on or three days after IESD for the members in denominator. Description AAB ANTIBIOTIC MEDICATIONS Prescription Aminoglycosides Amikacin Tobramycin Gentamicin Streptomycin Aminopenicillins Amoxicillin Ampicillin Beta-lactamase inhibitors Amoxicillin-clavulanate Piperacillin-tazobactam Ticarcillin-clavulanate Ampicillin-sulbactam First-generation Cefadroxil Cefazolin Cephalexin cephalosporins Fourth-generation cephalosporins Cefepime Ketolides Telithromycin Lincomycin derivatives Clindamycin Lincomycin Azithromycin Erythromycin Erythromycin Macrolides Clarithromycin Erythromycin lactobionate ethylsuccinate Erythromycin stearate Aztreonam Daptomycin Metronidazole Miscellaneous antibiotics Chloramphenicol Erythromycin- Vancomycin Dalfopristin-quinupristin sulfisoxazole Linezolid Penicillin G benzathine- Penicillin G procaine Penicillin V potassium Natural penicillins procaine Penicillin G sodium Penicillin G Penicillin G potassium benzathine Penicillinase resistant Dicloxacillin Nafcillin Oxacillin penicillins Quinolones Ciprofloxacin Levofloxacin Norfloxacin Gemifloxacin Moxifloxacin Ofloxacin Rifamycin derivatives Rifampin Second-generation cephalosporin Cefaclor Cefoxitin Cefuroxime Cefotetan Cefprozil Sulfonamides Sulfadiazine Sulfamethoxazole-trimethoprim Tetracyclines Doxycycline Minocycline Tetracycline Cefdinir Cefotaxime Ceftibuten Third-generation Cefditoren Cefpodoxime Ceftriaxone cephalosporins Cefixime Ceftazidime Fosfomycin Nitrofurantoin macrocrystals-monohydrate Urinary anti-infectives Nitrofurantoin Nitrofurantoin macrocrystals Trimethoprim 13

15 Comprehensive Diabetes Care (CDC) HbA1c Control (<8.0) Methodology: HEDIS Measure Description: The percentage of Members years of age with diabetes (type 1 and type 2) who had the following: HbA1c Control (<8.0%) This includes diabetics whose most recent HbA1c test during the measurement year (2018) has a value <8.0%. - The Member is not numerator compliant if the result for the most recent HbA1c test is 8.0% or is missing a result, or if an HbA1c test was not done during the measurement year (2018). Eligible population in this measure meets all of the following criteria: 1. Members who are years as of December 31 of the measurement year (2018). 2. Continuous enrollment in the measurement year (2018) with no more than one gap of up to 45 days during the measurement year. 3. Members who met any of the following criteria during the measurement year (2018) or the year (2017) prior to the measurement year (count services that occur over both years): At least two outpatient visits, observation visits, ED visits or nonacute inpatient encounters on different dates of service, with a diagnosis of diabetes. Visit type need not be the same for the two visits. OR At least one acute inpatient encounter with a diagnosis of diabetes. OR Members who were dispensed insulin or hypoglycemics/ antihyperglycemics on an ambulatory basis during the measurement year (2018) or the year prior to the measurement year (2017). 14

16 CODES TO IDENTIFY HBA1C TESTS Service Code Type Code Code Description HbA1c Test (<7.0%) CPT-CAT-II 3044F Hg A1c Level Lt 7.0% HbA1c Test CPT Hemoglobin Glycated HbA1c Test CPT Hemoglobin; glycosylated (A1C) by device cleared by FDA for home use HbA1c Test CPT-CAT-II 3044F Most recent hemoglobin A1c (HbA1c) level < 7.0% HbA1c Test CPT-CAT-II 3045F Most recent hemoglobin A1c (HbA1c) level % HbA1c Test CPT-CAT-II 3046F Most recent hemoglobin A1c (HbA1c) level > 9.0% HbA1c Test LOINC Hemoglobin A1c/hemoglobin.total In Blood By Hplc HbA1c Test LOINC Hemoglobin A1c/hemoglobin.total In Blood HbA1c Test LOINC Hemoglobin A1c/hemoglobin.total In Blood By Electrophoresis Members who met any of the following criteria are excluded: 1. Members in hospice are excluded. 2. Members who do not have a diagnosis of diabetes, in any setting, during the measurement year (2018) or the year prior to the measurement year (2017) and who had a diagnosis of gestational diabetes or steroid-induced diabetes, in any setting, during the measurement year (2018) or the year prior to the measurement year (2017). Denominator: Members years of age who meet all the criteria for eligible population. Numerator: Members in the denominator who had the most recent HbA1c level <8 during the measurement year (2018). 15

17 Comprehensive Diabetes Care (CDC) Eye Exam Methodology: HEDIS Measure Description: The percentage of Members years of age with diabetes (type 1 and type 2) who had the following: Eye Exam (retinal) performed This includes diabetics who had one of the following: - A retinal or dilated eye exam by an eye care professional (optometrist or ophthalmologist) in the measurement year (2018) - A negative retinal or dilated eye exam (negative for retinopathy) by an eye care professional in the year prior to the measurement year (2018) Eligible population in this measure meets all of the following criteria: 1. Members who are years as of December 31 of the measurement year (2018). 2. Continuous enrollment in the measurement year (2018) with no more than one gap of up to 45 days during the measurement year. 3. Members who met any of the following criteria during the measurement year (2018) or the year prior to the measurement year (count services that occur over both years): At least two outpatient visits, observation visits, ED visits or nonacute inpatient encounters on different dates of service, with a diagnosis of diabetes. Visit type need not be the same for the two visits. OR At least one acute inpatient encounter with a diagnosis of diabetes. OR Members who were dispensed insulin or hypoglycemics/ antihyperglycemics on an ambulatory basis during the measurement year (2018) or the year prior to the measurement year. 16

18 Service Code Type CODES TO IDENTIFY EYE EXAMS Code Code Description CPT Intravitreal Injection Of A Pharmacologic Agent (separate Procedure) CPT Discission Of Vitreous Strands (without Removal) Pars Plana Approach CPT Severing Of Vitreous Strands Vitreous Face Adhesions Sheets Membranes Or Opacities Laser Surgery (one Or More Stages) CPT Vitrectomy Mechanical Pars Plana Approach CPT CPT CPT CPT CPT CPT CPT CPT CPT CPT CPT CPT Vitrectomy Mechanical Pars Plana Approach With Focal Endolaser Photocoagulation Vitrectomy Mechanical Pars Plana Approach With Endolaser Panre Tinal Photocoagulation Vitrectomy Mechanical Pars Plana Approach With Removal Of Preretinal Cellular Membrane (eg Macular Pucker) Vitrectomy Mechanical Pars Plana Approach With Removal Of Internal Limiting Membrane Of Retina (eg For Repair Of Macular Hole Vitrectomy mechanical pars plana approach, with removal of subretinal membrane (eg, Choroidal Neovascularization), includes, if performed, intraocular tamponade (ie, air, gas or silicone oil) Repair Retinal Detachment, Incld Drainage Of Subretinal Fluid When Performed; Cryotherapy Repair Retinal Detachment, Incld Drainage Of Subretinal Fluid When Performed; Photocoagulation Repair Of retinal detachment scleral buckling (such as lamellar scleral dissection, Imbrication or encircling procedure), including, when performed, implant, cryotherapy, photocoagulation, and drainage of subretinal fluid Repair Of Retinal Detachment With Vitrectomy Any Method With OR Without Air Or Gas Tamponade Focal Endolaser Photocoagulation Repair Of Retinal Detachment By Injection Of Air Or Other Gas (e G Pneumatic Retinopexy) Repair Of Retinal Detachment By Scleral Buckling Or Vitrectomy On Patient Having Previous Ipsilateral Retinal Detachment Repair Repair Of Complex Retinal Detachment (eg, Proliferative Vitreoretinopathy Stage C-1 or greater, diabetic Traction Retinal Detachment, retinopathy of prematurity, retinal tear of greater than 90 degrees), with vitrectomy and membrane peeling, including, when performed, air, gas, or silicone oil tamponade, cryotherapy, endolaser photocoagulation, drainage of subretinal fluid, scleral buckling, and/or removal of lens CPT Removal Of Implanted Material Posterior Segment Intraocular 17

19 Service Code Type CODES TO IDENTIFY EYE EXAMS Code CPT CPT CPT CPT CPT CPT CPT CPT CPT CPT CPT CPT CPT CPT CPT CPT CPT Code Description Prophylaxis Of Retinal Detachment (eg, retinal break lattice degeneration) without drainage, 1 or more sessions; cryotherapy, diathermy Prophylaxis Of Retinal Detachment (eg, retinal break lattice degeneration) without drainage, 1 or more sessions; photocoagulation (laser or xenon arc) Destruction Of Localized Lesion Of Retina (eg Macular Edema Tumors) One Or More Sessions Cryotherapy Diathermy Destruction Of Localized Lesion Of Retina (eg Macular Edema Tumors) One Or More Sessions Photocoagulation Destruction Of Localized Lesion Of Retina (eg Macular Edema Tumors) One Or More Sessions Radiation By Implantation Of Source Destruction Of Localized Lesion Of Choroid (eg Choroidal Neovasc Ularization) Photocoagulation (eg Laser) One Or More Sessions Destruction Of Localized Lesion Of Choroid (eg Choroidal Neovasc Ularization) Photodynamic Therapy (includes Intravenous Infusion Destruction Of Extensive Or Progressive Retinopathy (eg Diabetic Retinopathy) One Or More Sessions Cryotherapy Diathermy Destruction of extensive or progressive retinopathy (eg, Diabetic Retinopathy), 1 or more sessions; Photocoagulation Ophthalmological services: medical examination and evaluation with initiation of diagnostic and treatment program; Intermediate, new patient Ophthalmological services: medical examination and evaluation with initiation of diagnostic and treatment program; comprehensive, new patient, 1 or more visits Ophthalmological services: medical examination and evaluation with initiation or continuation of diagnostic and treatment program; intermediate, established patient Ophthalmological services: medical examination and evaluation with initiation or continuation of diagnostic and treatment program; comprehensive, established patient, 1 or more visits Ophthalmological examination and evaluation under general anesthesia with or without manipulation of globe for passive range of motion or other manipulation to facilitate diagnostic examination; complete Ophthalmological examination and evaluation under general anesthesia with or without manipulation of globe for passive range of motion or other manipulation to facilitate diagnostic examination; limited Scanning computerized ophthalmic diagnostic imaging posterior segment, with interpretation and report, unilateral or bilateral: optic nerve Ophthalmoscopy extended with retinal drawing (eg, for retinal detachment melanoma), with Interpretation and report; initial 18

20 Service Code Type CODES TO IDENTIFY EYE EXAMS Code CPT CPT CPT Code Description Ophthalmoscopy Extended With Retinal Drawing (eg For Retinal Detachment Melanoma) With Interpretation And Report Subsequent Remote imaging for detection of retinal disease (eg, Retinopathy in a patient with diabetes) with analysis and report under physician supervision, unilateral or bilateral Remote imaging for monitoring and management of active retinal disease (eg, Diabetic Retinopathy) with physician review, interpretatation and report, unilateral or bilateral CPT Fluorescein Angioscopy With Interpretation And Report CPT CPT Fluorescein Angiography (includes Multiframe Imaging) With Interpretation And Report (unilateral Or Bilateral) Indocyanine-green Angiography (includes Multiframe Imaging) With Interpretation And Report (unilateral Or Bilateral) CPT Fundus Photography With Interpretation And Report CPT Ophthalmodynamometry CPT CPT CPT CPT CPT CPT Office or other patient visit for the evaluation and management of a new patient, which requires these 3 key components: A detailed history: A detailed exam: Medical decision making of low complexity. Office or other patient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history: A comprehensive exam: Medical decision making of moderate complexity. Office or other patient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history: A comprehensive exam: Medical decision making of high complexity. Office or other patient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 components: An expanded problem focused history: An expanded problem focused examination: Medical decision making of low complexity. Office or other patient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 components: A detailed history: A detailed exam: Medical decision making of moderate complexity. Office or other patient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 components: A comprehensive history: A comprehensive exam: Medical decision making of high complexity. 19

21 Service Code Type CODES TO IDENTIFY EYE EXAMS Code CPT CPT CPT CPT S0620 S0621 Code Description Office consultation for a new or established patient which requires these 3 key components: An expanded problem focused history: An expanded problem focused examination: and, Straightforward medical decision making. Office consultation for a new or established patient which requires these 3 key components: A detailed history: A detailed exam: and, Medical decision making of low complexity. Office consultation for a new or established patient which requires these 3 key components: A comprehensive history: A comprehensive examination: and, Medical decision making of moderate complexity. Office consultation for a new or established patient which requires these 3 key components: A comprehensive history: A comprehensive examination: and, Medical decision making of high complexity. Routine Ophthalmological Examination Including Refraction; New Patient (s0620) Routine Ophthalmological Examination Including Refraction; Established Patient (s0621) S3000 Diabetic Indicator; Retinal Eye Exam, Dilated, Bilateral (s3000) Members who met any of the following criteria are excluded: 1. Members in hospice are excluded. 2. Members who do not have a diagnosis of diabetes, in any setting, during the measurement year (2018) or the year prior to the measurement year and who had a diagnosis of gestational diabetes or steroid-induced diabetes, in any setting, during the measurement year or the year prior to the measurement year. Denominator: Members years of age who meet all the criteria for eligible population. Numerator: Members in the denominator who had an eye exam during the measurement year (2018). 20

22 Medication Management for People with Asthma 75% rate (MMA) Methodology: HEDIS Measure Description: The percentage of Members 5 64 years of age during the measurement year (2018) who were identified as having persistent asthma and were dispensed appropriate medications that they remained on for at least 75% of their treatment period. (Treatment Period: The period of time beginning on the Index Prescription Start Date through 12/31/2018.) Eligible population in this measure meets all of the following criteria: 1. Age 5-64 as of December 31 of the measurement year (2018). 2. Continuous enrollment during the measurement year (2018) and the year prior to the measurement year (2017) with no more than one gap in enrollment of up to 45 days during each year of continuous enrollment. 3. a) At least one ED visit with a principal diagnosis of asthma OR b) At least one acute inpatient encounter with a principal diagnosis of asthma OR c) At least four outpatient visits or observation visits on different dates of service, with any diagnosis of asthma and at least two asthma medication dispensing events for any controller medication or reliever medication. Visit type need not be the same for the four visits OR d) At least four asthma medication dispensing events for any controller medication or reliever medication. Description ASTHMA CONTROLLER MEDICATIONS: Prescription Antiasthmatic Dyphylline-guaifenesin Guaifenesin-theophylline combinations Antibody inhibitors Omalizumab Anti-interleukin-5 Mepolizumab Reslizumab Inhaled steroid Budesonide-formoterol Fluticasone-vilanterol combinations Fluticasone-salmeterol Mometasone-formoterol Beclomethasone Flunisolide Inhaled corticosteroids Budesonide Fluticasone CFC free Ciclesonide Mometasone Leukotriene modifiers Montelukast Zafirlukast Zileuton Mast cell stabilizers Cromolyn Methylxanthines Dyphylline Theophylline ASTHMA RELIEVER MEDICATIONS Description Prescriptions Short-acting, inhaled beta-2 agonists Albuterol Levalbuterol Pirbuterol 21

23 Members who met any of the following criteria are excluded: 1. Members who had no asthma controller medications dispensed during the measurement year (2018). 2. Members in hospice are excluded. 3. Members with following diagnosis anytime during the member s history through December 31 of the measurement year (2018) are excluded: COPD, Acute Respiratory Failure, Cystic Fibrosis, Chronic respiratory conditions and Emphysema. Denominator: Members 5 64 years of age during the measurement year (2018) who were identified as having persistent asthma and were dispensed appropriate medications that they remained on during the treatment period. Numerator: Members in denominator who remained on an asthma controller medication for at least 75% of their treatment period. 22

24 Population: Adult and Adolescent for Clinical Methodology: IEHP-defined Quality Metric Modified from PQRS measure (NQF 0418) Measure Description: The percentage of Members aged 12 years and older screened for clinical depression on the date of the encounter using an age appropriate standardized depression screening tool during the measurement year (2018). Denominator: All Members aged 12 years and older with a Primary Care Provider (PCP) visit in the measurement year (2018). Member counted only once in the denominator. PRIMARY CARE PROVIDER VISIT CODES: Service Code Type Code Code Description for Clinical CPT Psychiatric diagnostic evaluation for Clinical CPT Psychiatric diagnostic evaluation with medical services for Clinical CPT Psychotherapy 30 minutes with patient for Clinical CPT Psychotherapy 45 minutes with patient for Clinical CPT Psychotherapy 60 minutes with patient for Clinical CPT Psychotherapy for crisis first 60 minutes for Clinical CPT Assessment of tinnitus for Clinical CPT Nubhvl status xm pr hr f2f w/pt interpj&prepj for Clinical CPT Nuropsyc tstg pr hr f2f w/pt + interpj time for Clinical CPT Assess hlth/behave init for Clinical CPT Assess hlth/behave subseq for Clinical CPT Occupational therapy evaluation Office or other outpatient visit for the evaluation and for Clinical CPT management of a new patient which requires these three key components: a 23

25 PRIMARY CARE PROVIDER VISIT CODES: Service Code Type Code Code Description for Clinical for Clinical for Clinical for Clinical for Clinical for Clinical for Clinical for Clinical for Clinical for Clinical for Clinical for Clinical for Clinical CPT CPT CPT CPT CPT CPT CPT CPT G0101 G0402 G0438 G0439 Office or other outpatient visit for the evaluation and management of a new patient which requires these three key components: an Office or other outpatient visit for the evaluation and management of a new patient which requires these three key components: a Office or other outpatient visit for the evaluation and management of a new patient which requires these three key components: a Office or other outpatient visit for the evaluation and management of a new patient which requires these three key components: a Office or other outpatient visit for the evaluation and management of an established patient which requires at least two of these Office or other outpatient visit for the evaluation and management of an established patient which requires at least two of these Office or other outpatient visit for the evaluation and management of an established patient which requires at least two of these Office or other outpatient visit for the evaluation and management of an established patient which requires at least two of these Cervical or vaginal cancer screening; pelvic and clinical breast examination Initial preventive physical examination face-to-face visits services limited to new beneficiary during the first 12 months Annual wellness visit includes a personalized prevention plan of service (pps) initial visit Annual wellness visit includes a personalized prevention plan of service (pps) subsequent visit G0444 Annual depression screening 15 minutes Numerator: Members screened for clinical depression on the date of the encounter using an age appropriate standardized tool. 24

26 CODES TO IDENTIFY SCREENING FOR CLINICAL DEPRESSION Service Code Type Code Code Description for Clinical CPT 1220F Patient screened for depression (sud) for Clinical for Clinical for Clinical for Clinical for Clinical for Clinical for Clinical for Clinical for Clinical for Clinical for Clinical CPT CPT CPT CPT 3351F 3352F 3353F 3354F Negative screen for depressive symptoms as categorized by using a standardized depression screening/ assessment tool (mdd) No significant depressive symptoms as categorized by using a stan dardized depression assessment tool (mdd) Mild to moderate depressive symptoms as categorized by using a standardized depression screening/ assessment tool (mdd) Clinically significant depressive symptoms as categorized by usin g a standardized depression screening/assessment tool (mdd) CPT 3725F for depression performed (dem) G0444 Annual depression screening 15 minutes G8431 G8433 G8510 G8511 G8940 Positive screen for clinical depression using a standardized tool and a follow-up plan documented for clinical depression using a standardized tool not documented patient not eligible/appropriate Negative screen for clinical depression using a standardized tool patient not eligible/appropriate for follow-up plan documented Screen for clinical depression using a standardize tool documented follow up plan not documented reason not specified for clinical depression documented follow-up plan not documented patient not eligible/ appropriate Definitions: Completion of a clinical or diagnostic tool used to identify people at risk of developing or having a certain disease or condition, even in the absence of symptoms. Standardized Depression Tool A normalized and validated depression screening tool developed for the Member population in which it is being utilized. The name of the age appropriate standardized depression screening tool utilized must be documented in the medical record. 25

27 Examples of depression screening tools include but are not limited to: Adolescent Tools (12-17 years): Patient Health Questionnaire for Adolescents (PHQ-A), Beck Depression Inventory-Primary Care Version (BDI-PC), Mood Feeling Questionnaire (MFQ), Center for Epidemiologic Studies Depression Scale (CES-D), and PRIME MD-PHQ2 Adult Tools (18 years and older): Patient Health Questionnaire (PHQ-9 or PHQ-2), Beck Depression Inventory (BDI or BDI-II), Center for Epidemiologic Studies Depression Scale (CES-D), Depression Scale (DEPS), Duke Anxiety-Depression Scale (DADS), Geriatric Depression Scale (GDS), Cornell Scale, and PRIME MD-PHQ2 Positive Depression with Follow Up Plan Methodology: IEHP-defined Quality Metric Modified from PQRS measure (NQF 0418) Measure Description: The percentage of Members aged 12 years and older who screened positive for clinical depression using an age appropriate standardized depression screening tool who also have a follow-up plan documented during the measurement year (2018). Denominator: All Members aged 12 years and older with a Primary Care Provider (PCP) visit with a positive depression screening in the measurement year (2018). Member counted only once in the denominator. CODES TO IDENTIFY POSITIVE DEPRESSION SCREENING DURING A PRIMARY CARE PROVIDER VISIT: Service Code Type Code Code Description Positive Depression with Follow Up Plan Positive Depression with Follow Up Plan Positive Depression with Follow Up Plan Positive Depression with Follow Up Plan Positive Depression with Follow Up Plan CPT CPT 3353F 3354F G8431 G8511 G8940 Mild to moderate depressive symptoms as categorized by using a standardized depression screening/assessment tool (mdd) Clinically significant depressive symptoms as categorized by using a standardized depression screening/assessment tool (mdd) Positive screen for clinical depression using a standardized tool and a follow-up plan documented Screen for clinical depression using a standardize tool documented follow up plan not documented reason not specified for clinical depression documented follow-up plan not documented patient not eligible/ appropriate 26

28 Numerator: Members screened positive for clinical depression with a follow-up plan documented during the measurement year (2018). CODES TO IDENTIFY POSITIVE DEPRESSION SCREENING WITH FOLLOW-UP PLAN Service Code Type Code Code Description Positive Depression Plan for follow-up care for major depressive disorder CPT 0545F with Follow Up Plan documented (mdd adol) Positive Depression Positive screen for clinical depression using a G8431 with Follow Up Plan standardized tool and a follow-up plan documented Positive Depression with Follow Up Plan G8940 for clinical depression documented follow-up plan not documented patient not eligible/ appropriate Definitions: Follow-Up Plan Documented follow-up for a positive depression screening must include one or more of the following: Additional evaluation for depression Suicide Risk Assessment Referral to a practitioner who is qualified to diagnose and treat depression Pharmacological interventions Other interventions or follow-up for the diagnosis or treatment of depression 27

29 Population: Women Breast Cancer (BCS) Methodology: HEDIS Measure Description: The percentage of women years of age who had a mammogram to screen for breast cancer any time on or between October 1 two years prior to the measurement year (2016) and December 31 of the measurement year (2018). Eligible population in the measure meets all of the following criteria: 1. Women years as of December 31 of the measurement year (2018). 2. Continuous enrollment from October 1 two years prior to the measurement year (2016) through December 31 of the measurement year (2018) with no more than one gap in enrollment of up to 45 days for each calendar year of continuous enrolment. No gaps in enrollment are allowed from October 1 two years prior to the measurement year (2016) through December 31 two years prior to the measurement year (2016). CODES USED TO IDENTIFY MAMMOGRAPHY Service Code Type Code Code Description Breast Cancer CPT Mammography Unilateral Breast Cancer CPT Mammography Bilateral Breast Cancer CPT Mammography Bilateral (2-view Film Study Of Each Breast) Breast Cancer CPT Digital Breast Tomosynthesis Unilateral Breast Cancer CPT Digital Breast Tomosynthesis Bilateral Breast Cancer CPT Digital Breast Tomosynthesis Bilateral (list Separately In Addition To Code For Primary Procedure) Breast Cancer CPT Diagnostic Mammography W/computer-aided Detection; Unilateral Breast Cancer CPT Diagnostic Mammography W/computer-aided Detection; Bilateral Breast Cancer CPT Mammography Bilateral (2-view Film Study Of Each Breast Including Computer-aided Detection (cad) Breast Cancer G0202 Mammography, Bilateral (2-view Study Of Each Breast), Including Computer-aided Detection (cad) When Performed (g0202) Breast Cancer G0204 Diagnostic Mammography, Including Computer-aided Detection (cad) When Performed; Bilateral (g0204) Breast Cancer G0206 Diagnostic Mammography, Including Computer-aided Detection (cad) When Performed; Unilateral (g0206) 28

30 Members who met any of the following criteria are Excluded: 1. Members who have had a bilateral mastectomy anytime during their history through December 31, 2018 may be excluded. To exclude Members who meet the exclusion criteria, please complete Member Historical Data Form and fax to IEHP s Quality Informatics Team at: A copy of the Historical Data Form is available in Appendix Members in hospice are excluded. Denominator: Women years of age who met the criteria for eligible population. Numerator: Members in denominator who had one or more mammograms any time on or between October 1 two years prior to the measurement year (2016) and December 31 of the measurement year (2018). (CCS) Methodology: HEDIS Measure Description: The percentage of Women years of age who were screened for cervical cancer using either of the following criteria: Women age who had cervical cytology performed every 3 years. Women age who had cervical cytology/human papillomavirus (HPV) co-testing performed every 5 years. Eligible population in the measure meets all of the following criteria: 1. Women years as of December 31 of the measurement year (2018). 2. Continuous enrollment during the measurement year (2018) with no more than one gap in enrollment of up to 45 days during each year of continuous enrollment. CODES TO IDENTIFY CERVICAL CYTOLOGY Service Code Type Code Code Description CPT CPT Cytopathology Cervical Or Vaginal (any Reporting System) Requiring Interpretation By Physician (List separately In addition to code for technical service.) Cytopathology Cervical Or Vaginal (any Reporting System) Collected In Preservative Fluid Automated Thin Layer Preparation Manual screening under physician supervision 29

31 CODES TO IDENTIFY CERVICAL CYTOLOGY Service Code Type Code Code Description CPT CPT CPT CPT CPT CPT CPT CPT CPT CPT CPT CPT CPT G0123 G0124 Cytopathology Cervical Or Vaginal (any Reporting System) Collec Ted In Preservative Fluid Automated Thin Layer Preparation; manual screening under physician supervision: With manual screening and rescreening under physician supervision Cytopathology Smears Cervical Or Vaginal By Automated System Under Physician Supervision Cytopathology Smears Cervical Or Vaginal By Automated System With Manual Rescreening Under Physician Supervision Cytopathology Slides Cervical Or Vaginal Manual Under Physician Supervision Cytopathology Slides Cervical Or Vaginal With Manual And Computer-assisted Rescreening Under Physician Supervision Cytopathology Slides Cervical Or Vaginal With Manual And Rescreening Under Physician Supervision Cytopathology Slides Cervical Or Vaginal With Manual And Computer-assisted Rescreening Using Cell Selection And Review under physician supervision Cytopathology Slides Cervical Or Vaginal (the Bethesda System) Manual Under Physician Supervision Cytopathology Slides Cervical Or Vaginal (the Bethesda System) With Manual And Rescreening Under Physician Supervision Cytopathology Slides Cervical Or Vaginal (the Bethesda System) With Manual And Computer-assisted Rescreening Under Physician supervision Cytopathology Slides Cervical Or Vaginal (the Bethesda System) With Manual And Computer-assisted Rescreening Using cell selection and review under physician supervision Cytopathology Cervical Or Vaginal (any Reporting System) Collected In Preservative Fluid Automated Thin Layer Preparation Cytopathology Cervical Or Vaginal (any Reporting System) Collected In Preservative Fluid Automated By System Cytopathology, Cervical Or Vaginal (any Reporting System), Collected In Preservative Fluid, Automated Thin Layer Preparation, By Cytotechnologist Under Physician Supervision (g0123) Cytopathology, Cervical Or Vaginal (any Reporting System), Collected In Preservative Fluid, Automated Thin Layer Preparation, Requiring Interpretation By Physician (g0124) 30

32 CODES TO IDENTIFY CERVICAL CYTOLOGY Service Code Type Code Code Description LOINC LOINC LOINC LOINC LOINC LOINC LOINC G0141 G0143 G0144 G0145 G0147 G0148 P3000 P3001 Q0091 Cytopathology Smears, Cervical Or Vaginal, Performed By Automated System, With Manual Rescreening, Requiring Interpretation By Physician (g0141) Cytopathology, Cervical Or Vaginal (any Reporting System), Collected In Preservative Fluid, Automated Thin Layer Preparation, With Manual And Rescreening By Cytotechnologist Under Physician Supervision (g0143) Cytopathology, Cervical Or Vaginal (any Reporting System), Collected In Preservative Fluid, Automated Thin Layer Preparation, With By Automated System, Under Physician Supervision (g0144) Cytopathology, Cervical Or Vaginal (any Reporting System), Collected In Preservative Fluid, Automated Thin Layer Preparation, With By Automated System And Manual Rescreening Under Physician Supervision (g0145) Cytopathology Smears, Cervical Or Vaginal, Performed By Automated System Under Physician Supervision (g0147) Cytopathology Smears, Cervical Or Vaginal, Performed By Automated System With Manual Rescreening (g0148) Papanicolaou Smear, Cervical Or Vaginal, Up To Three Smears, By Technician Under Physician Supervision (p3000) Papanicolaou Smear, Cervical Or Vaginal, Up To Three Smears, Requiring Interpretation By Physician (p3001) Papanicolaou Smear; Obtaining, Preparing And Conveyance Of Cervical Or Vaginal Smear To Laboratory (q0091) Microscopic Observation [identifier] In Cervix By Cyto Stain Microscopic Observation [identifier] In Cervix By Cyto Stain Thinprep General Categories [interpretation] Of Cervical Or Vaginal Smear Or Scraping By Cyto Stain Statement Of Adequacy [interpretation] Of Cervical Or Vaginal Smear Or Scraping By Cyto Stain Microscopic Observation [identifier] In Cervical Or Vaginal Smear Or Scraping By Cyto Stain Microscopic Observation [identifier] In Cervical Or Vaginal Smear Or Scraping By Cyto Stain Narrative Cytology Study Comment Cervical Or Vaginal Smear Or Scraping Cyto Stain 31

33 CODES TO IDENTIFY CERVICAL CYTOLOGY Service Code Type Code Code Description LOINC Cytology Cervical Or Vaginal Smear Or Scraping Study Cytology Report Of Cervical Or Vaginal Smear Or Scraping Cyto LOINC Stain.thin Prep Cytology Report Of Cervical Or Vaginal Smear Or Scraping Cyto LOINC Stain CODES TO IDENTIFY HPV TESTS Service Code Type Code Code Description Infectious Agent Detection By Nucleic Acid (dna Or Rna) CPT Papillom Avirus Human Direct Probe Technique Infectious Agent Detection By Nucleic Acid (dna Or Rna) CPT Papillom Avirus Human Amplified Probe Technique Infectious Agent Detection By Nucleic Acid (dna Or Rna) CPT Papillom Avirus Human Quantification Infectious Agent Detection By Nucleic Acid (dna Or Rna) CPT Human Pap Illomavirus (hpv) High-risk Types (eg ) CPT LOINC G LOINC LOINC LOINC LOINC LOINC LOINC Infectious Agent Detection By Nucleic Acid (dna Or Rna) Human Pap Illomavirus (hpv) Types 16 And 18 Only Includes Type 45, If Performed Infectious Agent Detection By Nucleic Acid (dna Or Rna); Human Papillomavirus (hpv), High-risk Types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) For, Must Be Performed In Addition To Pap Test (g0476) Human Papilloma Virus Dna [presence] In Cervix By Dna Probe Human Papilloma Virus Dna [presence] In Cervix By Probe And Signal Amplification Method Human Papilloma Virus Dna [presence] In Cervix By Probe And Signal Amplification Method Human Papilloma Virus 16 Dna [presence] In Cervix By Probe And Signal Amplification Method Human Papilloma Virus 18 Dna [presence] In Cervix By Probe And Signal Amplification Method Human Papilloma Virus Dna [presence] In Cervix By Probe And Signal Amplification Method Human Papilloma Virus E6+e7 Mrna [presence] In Cervix By Probe And Target Amplification Method 32

34 CODES TO IDENTIFY HPV TESTS Service Code Type Code Code Description LOINC LOINC LOINC LOINC LOINC LOINC LOINC LOINC Human Papilloma Virus Dna [presence] In Cervix By Probe And Target Amplification Method Human Papilloma Virus E6+e7 Mrna [presence] In Cervix By Probe And Target Amplification Method Human Papiloma Virus 16 And 18 And Dna [interpretation] In Cervix Human Papilloma Virus 16 Dna [presence] In Cervix By Probe And Target Amplification Method Human Papilloma Virus 18 Dna [presence] In Cervix By Probe And Target Amplification Method Human Papilloma Virus 16 And E6+e7 Mrna [identifier] In Cervix By Probe And Target Amplification Method Human Papilloma Virus 16 E6+e7 Mrna [presence] In Cervix By Probe And Target Amplification Method Human Papilloma Virus Dna [presence] In Cervix By Probe And Target Amplification Method Members who met any of the following criteria are Excluded: 1. Members whom have had a hysterectomy with no residual cervix, cervical agenesis or acquired absence of cervix any time during their history through December 31, 2018 may be excluded. To exclude Members who meet the exclusion criteria, please complete Member Historical Data Form and fax to IEHP s Quality Informatics Team at: A copy of the Historical Data Form is available in Appendix Members in hospice are excluded. Denominator: Women years of age who met the criteria for eligible population. Numerator: Women in the denominator who were screened timely for cervical cancer. 33

35 Timeliness of Prenatal Care (PPC) Methodology: HEDIS Measure Description: The percentage of deliveries of live births on or between November 6, 2017 and November 5, 2018 that received a prenatal care visit as a Member of the organization in the first trimester, on the enrollment start date or within 42 days of enrollment in the organization. Eligible population in this measure meets all of the following criteria: 1. Continuous enrollment 43 days prior to delivery through 56 days after delivery with no allowable gap. 2. Member who delivered a live birth on or between November 6 of the year prior to the measurement year (2017) and November 5 of the measurement year (2018). Include women who delivered in any setting. Multiple births - Women who had two separate deliveries (different dates of service) between November 6 of the year prior to the measurement year (2017) and November 5 of the measurement year (2018) count twice. Women who had multiple live births during one pregnancy count once. CODES TO IDENTIFY STAND ALONE PRENATAL VISITS Service Code Type Code Code Description Prenatal Visit CPT 0500F Initial Prenatal Care Visit Prenatal Visit CPT 0501F Prenatal Flow Sheet Prenatal Visit CPT 0502F Subsequent Prenatal Care Visit Prenatal Visit CPT Home Visit Prenatal Prenatal Visit H1000 Prenatal Care, At-risk Assessment Prenatal Visit H1001 Prenatal Care, At-risk Enhanced Service; Antepartum Management Prenatal Visit H1002 Prenatal Care, At Risk Enhanced Service; Care Coordination Prenatal Visit H1003 Prenatal Care, At-risk Enhanced Service; Education Prenatal Visit H1004 Prenatal Care, At-risk Enhanced Service; Follow-up Home Visit Prenatal Visit Z1032 Initial Antepartum Office Visit Prenatal Visit Z1034 Antepartum Follow-Up Visit Prenatal care visit to an OB/GYN or other prenatal care practitioner or PCP. For visits to a PCP, a diagnosis of pregnancy must be present. Documentation in the medical record must include a note indicating the date when the prenatal care visit occurred, and evidence of one of the following. A basic physical obstetrical examination that includes auscultation for fetal heart tone, or pelvic exam with obstetric observations, or measurement of fundus height (a standardized prenatal flow sheet may be used). 34

36 Evidence that a prenatal care procedure was performed, such as: test in the form of an obstetric panel (must include all of the following: hematocrit, differential WBC count, platelet count, hepatitis B surface antigen, rubella antibody, syphilis test, RBC antibody screen, Rh and ABO blood typing), or TORCH antibody panel alone, or A rubella antibody test/titer with an Rh incompatibility (ABO/Rh) blood typing, or Echography of a pregnant uterus. Documentation of LMP or EDD in conjunction with either of the following. Prenatal risk assessment and counseling/education. Complete obstetrical history. Members in hospice are excluded. Denominator: Members who delivered a live birth on or between November 6 of the year prior to the measurement year (2017) and November 5 of the measurement year (2018). Numerator: Members in the denominator who had a prenatal care visit as a member of the organization in the first trimester, on the enrollment start date or within 42 days of enrollment in the organization. Postpartum Care (PPC) Methodology: HEDIS Measure Description: The percentage of deliveries of live births on or between November 6, 2017 and November 5, 2018 that had a postpartum visit on or between 21 and 56 days after delivery. Eligible population in this measure meets all of the following criteria: 1. Continuous enrollment 43 days prior to delivery through 56 days after delivery with no allowable gap. 2. Member who delivered a live birth on or between November 6 of the year prior to the measurement year (2017) and November 5 of the measurement year (2018). Include women who delivered in any setting. Multiple births - Women who had two separate deliveries (different dates of service) between November 6 of the year prior to the measurement year (2017) and November 5 of the measurement year (2018) count twice. Women who had multiple live births during one pregnancy count once. 35

37 CODES TO IDENTIFY POSTPARTUM CARE Service Code Type Code Code Description Postpartum Care Postpartum Care Postpartum Care Postpartum Care Postpartum Care Postpartum Care Postpartum Care Postpartum Care Postpartum Care Postpartum Care Postpartum Care Postpartum Care Postpartum Care CPT Diaphragm Or Cervical Cap Fitting With Instructions CPT Insertion Of Intrauterine Device (iud) CPT Postpartum Care Only (separate Procedure) CPT Home Visit Postnatal CPT-CAT-II 0503F Postpartum Care Visit G0101 ICD10CM Z ICD10CM Z ICD10CM Z01.42 ICD10CM Z Cervical Or Vaginal Cancer ; Pelvic And Clinical Breast Examination (g0101) [z01.411] Encounter For Gynecological Examination (general) (routine) With Abnormal Findings [z01.419] Encounter For Gynecological Examination (general) (routine) Without Abnormal Findings [z01.42] Encounter For Cervical Smear To Confirm Findings Of Recent Normal Smear Following Initial Abnormal Smear [z30.430] Encounter For Insertion Of Intrauterine Contraceptive Device ICD10CM Z39.1 [z39.1] Encounter For Care And Examination Of Lactating Mother ICD10CM Z39.2 [z39.2] Encounter For Routine Postpartum Follow-up Z1038 Postpartum Follow-Up Office Visit Members in hospice are excluded. Denominator: Members who delivered a live birth on or between November 6 of the year prior to the measurement year (2017) and November 5 of the measurement year (2018). Numerator: Members in the denominator who had a postpartum visit on or between 21 and 56 days after delivery. 36

38 Population: Child Childhood Immunizations (CIS) Combo 10 Methodology: HEDIS Measure Description: The percentage of Children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV); one measles, mumps and rubella (MMR); three haemophilus influenza type B (HiB); three hepatitis B (HepB), one chicken pox (VZV); four pneumococcal conjugate (PCV); one hepatitis A (HepA); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday. The measure calculates a rate for each vaccine and two separate combination rates. Combo 10 includes the timely completion of the following antigens: - DTaP; IPV; MMR; HiB; HepB; VZV; PCV; HepA; Rotavirus; Flu Eligible population in this measure meets all of the following criteria: 1. Children who turn 2 years of age during the measurement year (2018). 2. Continuous enrollment 12 months prior to the child s second birthday with no more than one gap in enrollment of up to 45 days during the 12 months prior to the child s second birthday. CHILDHOOD IMMUNIZATION CODE SET Antigen Code Type Code Code Description DTaP CPT Diphtheria Tetanus Toxoids And Acellular Pertussis Vaccine And Hemophilus Influenza B Vaccine And Activated Poliovirus Vaccine, (DTaP-IPV/Hib), For Intramuscular Use DTaP CPT Diphtheria Tetanus Toxoids And Acellular Pertussis Vaccine (dta P) For Intramuscular Use DTaP CPT Diphtheria Tetanus Toxoids And Acellular Pertussis Vaccine And Hemophilus Influenza B Vaccine (dtap-hib) For Intramuscular Use DTaP CPT Diphtheria Tetanus Toxoids Acellular Pertussis Vaccine Hepatitis B, and Inactivated poliovirus vaccine (dtap-hepb-ipv), For Intramuscular Use IPV CPT Diphtheria Tetanus Toxoids And Acellular Pertussis Vaccine And Hemophilus Influenza B Vaccine and activated poliovirus vaccine, (DTaP- IPV/Hib), For Intramuscular Use IPV CPT Poliovirus Vaccine Inactivated (ipv) For Subcutaneous Use IPV CPT MMR CPT Diphtheria Tetanus Toxoids Acellular Pertussis Vaccine Hepatitis B, and Inactivated poliovirus vaccine (dtap-hepb-ipv), For Intramuscular Use Measles Mumps And Rubella Virus Vaccine (mmr) Live For Subcuta Neous Use 37

39 CHILDHOOD IMMUNIZATION CODE SET Antigen Code Type Code Code Description MMR CPT Measles Mumps Rubella And Varicella Vaccine (mmrv) Live For Subcutaneous Use HiB CPT Meningococcal Conjugate Vaccine, Serogroups C & Y And Hemophilus Influenzae Type B Vaccine (hib-mency), 4 dose schedule, When Administered to children 6 wks to 18 mos of age, for intramuscular use HiB CPT Hemophilus Influenza B Vaccine (hib) Hboc Conjugate (4 Dose Schedule) For Intramuscular Use HiB CPT Hemophilus Influenza B Vaccine (hib) Prp-d Conjugate For Booster Use Only Intramuscular Use HiB CPT Hemophilus Influenza B Vaccine (hib) Prp-omp Conjugate (3 Dose S Chedule) For Intramuscular Use HiB CPT Hemophilus Influenza B Vaccine (hib)prp-t Conjugate (4 Dose Sche Dule) For Intramuscular Use HiB CPT Diphtheria Tetanus Toxoids And Acellular Pertussis Vaccine And Hemophilus Influenza B Vaccine and activated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use HiB CPT Diphtheria Tetanus Toxoids And Acellular Pertussis Vaccine And Hemophilus Influenza B Vaccine (dtap-hib) For Intramuscular Use HiB CPT Hepatitis B And Hemophilus Influenza B Vaccine (hepb-hib) For Intramuscular Use HepB CPT Diphtheria Tetanus Toxoids Acellular Pertussis Vaccine Hepatitis B, and Inactivated poliovirus vaccine (dtap-hepb-ipv), For Intramuscular use HepB CPT Hepatitis B Vaccine Dialysis Or Immunosuppressed Patient Dosage (3 Dose Schedule) For Intramuscular Use HepB CPT Hepatitis B Vaccine Pediatric/adolescent Dosage (3 Dose Schedule ) For Intramuscular Use HepB CPT Hepatitis B Vaccine Dialysis Or Immunosuppressed Patient Dosage (4 Dose Schedule) For Intramuscular Use HepB CPT Hepatitis B And Hemophilus Influenza B Vaccine (hepb-hib) For Intramuscular Use HepB G0010 Administration Of Hepatitis B Vaccine (g0010) VZV CPT Measles Mumps Rubella And Varicella Vaccine (mmrv) Live For Subcutaneous Use VZV CPT Varicella Virus Vaccine Live For Subcutaneous Use PCV CPT Pneumococcal Conjugate Vaccine Polyvalent For Children Under Five Years For Intramuscular Use PCV CPT Pneumococcal Conjucate Vaccine 13 Valent For Intramuscular Use PCV G0009 Administration Of Pneumococcal Vaccine (g0009) HepA CPT Hepatitis A Vaccine Pediatric/adolescent Dosage-2 Dose Schedule For Intramuscular Use Rotavirus - 2 Dose CPT Rotavirus Vaccine Human Attenuated 2 Dose Schedule Live For Oral Use. 38

40 CHILDHOOD IMMUNIZATION CODE SET Antigen Code Type Code Code Description Rotavirus - 3 Dose CPT Rotavirus Vaccine Tetravalent Live For Oral Use Flu CPT Flu Virus Vaccine, Trivalent (iiv3), Split Virus, Preservative Free, 0.25ml Dosage, For Intramuscular Use Flu CPT Influenza Virus Vaccine Split Virus For Children 6-35 Months Of Age For Intramuscular Use Flu CPT Influenza Virus Vaccine Derived From Cell Cultures Subunit Preservative And Antibiotic Free For Intramuscular Use Flu CPT Influenza Virus Vaccine Split Virus Preservative Free Enhanced Immunogenicity Via Increased Antigen Content, For Intramuscular use Flu CPT Influenza Virus Vaccine Trivalent Derived From Recombinant Dna (r Iv3) Hemagglutinin (ha) Protein Only Preservative And Antibiotic Flu CPT Influenza Virus Vaccine Quadrivalent (II4V) Split Virus preservative free, 0.25 ml dosage, for Intramuscular Use Flu CPT Influenza Virus Vaccine Quadrivalent (II4V) Split Virus preservative free, 0.5 ml dosage, for Intramuscular use Flu CPT Influenza Virus Vaccine Quadrivalent (II4V) Split Virus, 0.25 ml dosage, for Intramuscular Use Flu CPT Influenza Virus Vaccine Quadrivalent (II4V) Split Virus, 0.5 ml dosage, for Intramuscular uuse Flu G0008 Administration Of Influenza Virus Vaccine (g0008) Members who met any of the following criteria are excluded: 1. Members in hospice are excluded. 2. Children who had a contraindication for a specific vaccine are excluded from the denominator for all antigen rates and the combination rates. Denominator: Children 2 years of age in the eligible population. Numerator: Members in denominator who show timely completion of all antigens in combo10. 39

41 Immunizations for Adolescents (IMA) Methodology: HEDIS Measure Description: The percentage of Adolescents 13 years of age who had one dose of meningococcal conjugate vaccine, one tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccine and three doses of the human papillomavirus (HPV) vaccine on or before their 13th birthday. The measure calculates a rate for each vaccine and a combination rate. At least one dose of meningococcal conjugate vaccine on or between the member s 11th and 13th birthdays At least one tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccine on or between the member s 11th and 13th birthdays At least two or three doses of the human papillomavirus (HPV) vaccine on or between the member s 9th and 13th birthdays; there must be at least 146 days between the first and second dose of the HPV vaccine Eligible population in this measure meets all of the following criteria: 1. Adolescents who turn 13 years of age during the measurement year (2018). 2. Continuous enrollment 12 months prior to the member s 13th birthday with no more than one gap in enrollment of up to 45 days during the 12 months prior to the 13th birthday. CODES TO IDENTIFY MENINGOCOCAL Antigen Code Type Code Code Description Meningococcal conjugate CPT Meningococcal Conjugate Vaccine Serogroups A, C, Y and W-135, quadrivalent (MCV4 or MenACWY), for Intramuscular use CODES TO IDENTIFY TDAP Antigen Code Type Code Code Description Tdap CPT Tetanus Diphtheria Toxoids And Acellular Pertussis Vaccine (Tdap) When Administered To Individuals 7 Years Or Older For Intramuscular Use 40

42 CODES TO IDENTIFY HPV Antigen Code Type Code Code Description HPV CPT HPV CPT HPV CPT Human Papilloma Virus (hpv) Vaccine Types Quadrivalent (4vHPV), 3 Dose Schedule, For Intramuscular Use Human Papilloma Virus (hpv) Vaccine Types 16, 18 bivalent (2vHPV) 3 Dose Schedule, For Intramuscular Use Human Papilloma Virus Vaccine , nonavalent (9vHPV) 3 Dose Schedule, For Intramuscular Use Members who met any of the following criteria are excluded: 1. Members in hospice are excluded. 2. Adolescents who had a contraindication for a specific vaccine are excluded from the denominator for all antigen rates and the combination rates. Denominator: Adolescents 13 years of age who meet all the criteria for eligible population. Numerator: Members in the denominator who had one dose of meningococcal conjugate vaccine, one tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccine, and have completed the human papillomavirus (HPV) vaccine series by their 13th birthday during the measurement year (2018). 41

43 Years of life (W34) Methodology: HEDIS Measure Description: The percentage of Members 3 6 years of age who had one or more well-child visits with a PCP during the measurement year (2018). Eligible population in this measure meets all of the following criteria: 1. Age 3-6 years as of December 31 of the measurement year (2018). 2. Continuous enrollment in the measurement year (2018) with no more than one gap in enrollment of up to 45 days. CODES TO IDENTIFY WELL-CHILD (NOTE: These codes must be provided by a Primary Care Provider in an office setting.) Service Code Type Code Code Description CPT CPT CPT CPT CPT CPT Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient: infant (age younger than 1 year) Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient: early childhood (age 1 through 4 years) Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient: late childhood (age 5 through 11 years) Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient: adolescent (age 12 through 17 years) Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient: (age 18 through 39 years) Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) 42

44 CODES TO IDENTIFY WELL-CHILD (NOTE: These codes must be provided by a Primary Care Provider in an office setting.) Service Code Type Code Code Description CPT CPT CPT CPT CPT G0438 G0439 ICD10CM Z00.00 ICD10CM Z00.01 Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; (age 18 through 39 years) Initial Care Per Day For Evaluation And Management Of Normal Ne Wborn Infant Seen In Other Than Hospital Or Birthing Center Annual Wellness Visit; Includes A Personalized Prevention Plan Of Service (pps), Initial Visit (g0438) Annual Wellness Visit, Includes A Personalized Prevention Plan Of Service (pps), Subsequent Visit (g0439) Encounter For General Adult Medical Examination Without Abnormal Findings Encounter For General Adult Medical Examination With Abnormal Findings ICD10CM Z Health Examination For Newborn Under 8 Days Old ICD10CM Z Health Examination For Newborn 8 To 28 Days Old ICD10CM Z ICD10CM Z Encounter For Routine Child Health Examination With Abnormal Findings Encounter For Routine Child Health Examination Without Abnormal Findings ICD10CM Z00.5 Encounter For Examination Of Potential Donor Of Organ And Tissue ICD10CM Z00.8 Encounter For Other General Examination ICD10CM Z02.0 Encounter For Examination For Admission To Educational Institution 43

45 CODES TO IDENTIFY WELL-CHILD (NOTE: These codes must be provided by a Primary Care Provider in an office setting.) Service Code Type Code Code Description ICD10CM Z02.1 Encounter For Pre-employment Examination ICD10CM Z02.2 Encounter For Examination For Admission To Residential Institution ICD10CM Z02.3 Encounter For Examination For Recruitment To Armed Forces ICD10CM Z02.4 Encounter For Examination For Driving License ICD10CM Z02.5 Encounter For Examination For Participation In Sport ICD10CM Z02.6 Encounter For Examination For Insurance Purposes ICD10CM Z02.71 Encounter For Disability Determination ICD10CM Z02.79 Encounter For Issue Of Other Medical Certificate ICD10CM Z02.81 Encounter For Paternity Testing ICD10CM Z02.82 Encounter For Adoption Services ICD10CM Z02.83 Encounter For Blood-alcohol And Blood-drug Test ICD10CM Z02.89 Encounter For Other Administrative Examinations ICD10CM Z02.9 Encounter For Administrative Examinations, Unspecified Members in hospice are excluded. Denominator: Members 3-6 years of age who meet all the criteria for eligible population. Numerator: Members in the denominator who had at least one well-child visit with a PCP during the measurement year (2018). The well-child visit must occur with a PCP, but the PCP does not have to be the practitioner assigned to the child. 44

46 Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents (WCC) Methodology: HEDIS Measure Description: The percentage of Members 3 17 years of age who had an outpatient visit with a PCP or OB/GYN and who had evidence of the following during the measurement year (2018). Report each of the three indicators below. BMI percentile documentation* Counseling for nutrition Counseling for physical activity Eligible population in this measure meets all of the following criteria: 1. Members who are 3-17 years of age as of December 31 of the measurement year (2018). 2. Continuous enrollment in the measurement year (2018) with no more than one gap up to 45 days. 3. An outpatient visit with a PCP or an OB/GYN during the measurement year (2018). * Because BMI norms for youth vary with age and gender, this measure evaluates whether BMI percentile is assessed rather than an absolute BMI value. CODES TO IDENTIFY BMI PERCENTILE Code Code Type Description Z68.51 ICD10 Body Mass Index (BMI) Pediatric, Less Than 5th Percentile For Age Z68.52 ICD10 Body Mass Index (BMI) Pediatric, 5th Percentile To Less Than 85th Percentile For Age Z68.53 ICD10 Body Mass Index (BMI) Pediatric, 85th Percentile To Less Than 95th Percentile For Age Z68.54 ICD10 Body Mass Index (BMI) Pediatric, Greater Than Or Equal To 95th Percentile For Age CODES TO IDENTIFY COUNSELING FOR PHYSICAL ACTIVITY Code Code Type Description G0447 Face-to-face Behavioral Counseling For Obesity, 15 Minutes S9451 Exercise Classes, Non-physician Provider, Per Session Z02.5 ICD10 Encounter For Examination For Participation In Sport Z71.82 ICD10 Exercise Counseling 45

47 CODES TO IDENTIFY COUNSELING FOR NUTRITION Code Code Type Description CPT Medical Nutrition Therapy Initial Assessment And Intervention Individual Face-toface With The Patient Each 15 Minutes CPT Medical Nutrition Therapy Re-assessment And Intervention Individual Face-to-face With The Patient Each 15 Minutes CPT Medical Nutrition Therapy Group (2 Or More Individual(s)) Each 30 Minutes G0270 Medical Nutrition Therapy; Reassessment And Subsequent Intervention(s) Following Second Referral In Same Year For Change In Diagnosis, Medical Condition Or Treatment Regimen (including Additional Hours Needed For Renal Disease), Individual, Face To Face G0271 Medical Nutrition Therapy, Reassessment And Subsequent Intervention(s) Following Second Referral In Same Year For Change In Diagnosis, Medical Condition, Or Treatment Regimen (including Additional Hours Needed For Renal Disease), Group (2 Or More Individuals) G0447 Face-to-face Behavioral Counseling For Obesity, 15 Minutes (G0447) S9449 Weight Management Classes, Non-physician Provider, Per Session (S9449) S9452 Nutrition Classes, Non-physician Provider, Per Session (S9452) S9470 Nutritional Counseling, Dietitian Visit (S9470) Z71.3 ICD10 Dietary Counseling And Surveillance Members who met any of the following criteria are excluded: 1. Members in hospice are excluded. 2. Female members who have a diagnosis of pregnancy during the measurement year (2018) are excluded. A diagnosis of pregnancy will be determined using claims and encounter data only. Denominator: Members 3-17 years of age who meet all the criteria for eligible population. Numerator: Members in the denominator who had evidence of BMI, counseling of nutrition or physical activity during the measurement year (2018). 46

48 Population: All Initial Health Assessment (IHA) Methodology: IEHP-Defined Compliance Metric Measure Description: The IHA is a comprehensive assessment that is completed during the Member s initial encounter with a Primary Care Physician (PCP), appropriate Medical Specialist, or Non-Physician Medical Provider and must be documented in the Member s medical record. The IHA enables the Member s PCP to assess and manage the acute, chronic and preventive health needs of the Member. IEHP provides PCPs a monthly detailed Member roster on the IEHP Provider portal for all newly enrolled IEHP Members who are due for an initial health assessment (IHA) 120 days of enrollment. Eligible population is newly assigned Members with IEHP effective enrollment date of 1/1/18 through 12/31/18. Initial Health Assessment must be provided within 120 days of enrollment (e.g., Member enrolled in December 2018 must be seen by April 2019 and PCP must submit encounter by May 2019) CODES TO IDENTIFY IHA VISITS Code Code Type Description CPT Office/Outpt E&M New Minor CPT Office/Outpt E&M New Low-Mod CPT Office/Outpt E&M New Mod Seve CPT Office/Outpt E&M New Mod-Hi CPT Office/Outpt E&M New Mod-Hi CPT Office/Outpt E&M Estab 5 Min CPT Office/Outpt E&M Estab Minor CPT Office/Outpt E&M Estab Low-Mo CPT Office/Outpt E&M Estab Mod-Hi CPT Office/Outpt E&M Estab Mod-Hi CPT Office Cons New/Estab Minor CPT Office Cons New/Est Lo Sever CPT Office Cons New/Estab Mod CPT Office Cons New/Estab Mod-Hi CPT Office Cons New/Estab Mod-Hi CPT Nursing Facility Care Init CPT Nursing Facility Care Init CPT Nursing Facility Care Init CPT Nursing Fac Care Subseq CPT Nursing Fac Care Subseq 47

49 CODES TO IDENTIFY IHA VISITS Code Code Type Description CPT Nursing Fac Care Subseq CPT Nursing Fac Care Subseq CPT Nurs Facil D/C Da Mgmt; 30 M CPT Nurs Facil D/C Da Mgmt; > CPT Annual Nursing Fac Assessmnt CPT Domicil/R-Home Visit New Pat CPT Domicil/R-Home Visit New Pat CPT Domicil/R-Home Visit New Pat CPT Domicil/R-Home Visit New Pat CPT Domicil/R-Home Visit New Pat CPT Domicil/R-Home Visit Est Pat CPT Domicil/R-Home Visit Est Pat CPT Domicil/R-Home Visit Est Pat CPT Domicil/R-Home Visit Est Pat CPT Home Visit E&M New Pt Lo Sev CPT Home Visit E&M New Pt Mod Se CPT Home Visit E&M New Pt Mod-Hi CPT Home Visit E&M New Pt Hi Sev CPT Home Visit E&M New Pt Unstbl CPT Home Visit E&M Estab Minor CPT Home Visit E&M Estab Low-Mod CPT Home Visit E&M Estab Mod-Hi CPT Home Visit E&M Estab Mod-Hi CPT Prolong Md Serv Outpt W/Pt; CPT Prolong Md Serv Outpt W/Pt; CPT Init Preven Meds E&M New Pt; CPT Init Preven Meds E&M New Pt; CPT Init Preven Meds E&M New Pt; CPT Init Preven Meds E&M New Pt; CPT Init Preven Meds E&M New Pt; CPT Init Preven Meds E&M New Pt; CPT Init Preven Meds E&M New Pt; CPT Preven Meds E&M Estab Pt; In CPT Preven Meds E&M Estab Pt; CPT Preven Meds E&M Estab Pt; CPT Preven Meds E&M Estab Pt; CPT Preven Meds E&M Estab Pt; CPT Preven Meds E&M Estab Pt; CPT Preven Meds E&M Estab Pt; CPT Preven Med Counsl (Sep Pro); 48

50 CODES TO IDENTIFY IHA VISITS Code Code Type Description CPT Preven Med Counsl (Sep Pro); CPT Preven Med Counsl (Sep Pro); CPT Preven Med Counsl (Sep Pro); CPT Preven Med Counsl Grp (Sep P CPT Preven Med Counsl Grp (Sep P CPT Admin/Intrpt Health Risk Ass CPT Unlisted Preven Meds Serv CPT Online E/M By Phys CPT Interprof Phone/Online CPT Interprof Phone/Online CPT Interprof Phone/Online CPT Interprof Phone/Online 31/> CPT Basic Life &/Or Disability E CPT Work Relat/Disabl Exam-Treat CPT Work Relat/Disabl Exam-Not T G0402 Initial Preventive Exam G0438 Ppps Initial Visit G0439 Ppps Subseq Visit G0463 Hospital Outpt Clinic Visit T1015 Clinic Service Z00.00 ICD10CM Encntr For General Adult Z00.01 ICD10CM Encounter For General Ad Z ICD10CM Encounter For Routine Ch Z ICD10CM Encntr For Routine Child Z00.5 ICD10CM Encounter For Exam Of Po Z00.8 ICD10CM Encounter For Other Gene Z02.0 ICD10CM Encounter For Exam For A Z02.1 ICD10CM Encounter For Pre-Employ Z02.2 ICD10CM Encounter For Exam For A Z02.3 ICD10CM Encounter For Examinatio Z02.4 ICD10CM Encounter For Examinatio Z02.5 ICD10CM Encounter For Examinatio Z02.6 ICD10CM Encounter For Examinatio Z02.71 ICD10CM Encounter For Disability Z02.79 ICD10CM Encounter For Issue Of O Z02.81 ICD10CM Encounter For Paternity Z02.82 ICD10CM Encounter For Adoption S Z02.83 ICD10CM Encounter For Blood-Alco Z02.89 ICD10CM Encounter For Other Admi Z02.9 ICD10CM Encounter For Administra 49

51 Concurrent Use of Opioids and Benzodiazepines Methodology: IEHP-Defined Compliance Metric Measure Description: The Concurrent Use of Opioids and Benzodiazepines measure specification is developed and maintained by the Pharmacy Quality Alliance (PQA). This measure examines the percentage of individuals 18 years and older with concurrent use of prescription opioids and benzodiazepines. The denominator includes individuals 18 years and older by the first day of the measurement year with 2 or more prescription claims for opioids filled on 2 or more separate days, for which the sum of the days supply is 15 or more days during the measurement period. The numerator includes individuals from the denominator with 2 or more prescription claims for benzodiazepines filled on 2 or more separate days, and concurrent use of opioids and benzodiazepines for 30 or more cumulative days. Exclusion: Patients in hospice care and those with a cancer diagnosis are excluded. Access to Care Needed Right Away Methodology: Monthly Member Satisfaction Survey Measure Description: In the last 6 months, when you needed care right away, how often did you get care as soon as you needed? Valid response: never, sometimes, usually, always Target response: usually, always Measure Support: To help identify opportunities to improve customer service, IEHP conducts a monthly Member Satisfaction Survey between June-December annually. Member survey responses are analyzed and shared at the PCP level. 50

52 Coordination of Care Methodology: Monthly Member Satisfaction Survey Measure Description: In the last 6 months, how often did your Personal Doctor seem informed and up-to-date about the care you got from these doctors or other health providers? Valid response: never, sometimes, usually, always Target response: usually, always Measure Support: To help identify opportunities to improve customer service, IEHP conducts a monthly Member Satisfaction Survey between June-December annually. Member Survey responses are analyzed and shared at the PCP level. Rating of Access to Routine Care Methodology: Monthly Member Satisfaction Survey Measure Description: In the last 6 months, how often did you get an appointment for a check-up or routine care at a Doctor s office or clinic as soon as you needed? Valid response: never, sometimes, usually, always Target response: usually, always Measure Support: To help identify opportunities to improve customer service, IEHP conducts a monthly Member Satisfaction Survey between June-December annually. Member Survey responses are analyzed and shared at the IPA level. 51

53 APPENDIX 3: Historical Data Form 52

54 APPENDIX 4: Member Satisfaction Survey 53

55 APPENDIX 4: Member Satisfaction Survey (continued...) 54

GLOBAL P4P. Pay for Performance (P4P) Program Guide

GLOBAL P4P. Pay for Performance (P4P) Program Guide GLOBAL P4P Pay for Performance (P4P) Program Guide Contact: QualityPrograms@iehp.org Published: March 28, 2018 PROGRAM OVERVIEW This program guide provides an overview of the 2018 Global Quality Pay for

More information

2019 PHP PRIMARY CARE INCENTIVE

2019 PHP PRIMARY CARE INCENTIVE Primary Care Physicians (PCP) of Physicians Health Network (PHN) may be eligible for an incentive payment in accordance with this PHP PCP Incentive (hereinafter referred to as the PCP Incentive ). As described

More information

GLOBAL P4P. Pay for Performance (P4P) Program Guide

GLOBAL P4P. Pay for Performance (P4P) Program Guide GLOBAL P4P Pay for Performance (P4P) Program Guide Contact: QualityPrograms@iehp.org Published: March 28, 2018 PROGRAM OVERVIEW This program guide provides an overview of the 2018 Global Quality Pay for

More information

TABLE OF CONTENTS 2019 PCP

TABLE OF CONTENTS 2019 PCP TABLE OF CONTENTS Program Overview... 1 Performance Measures... 4 Scoring Methodology... 6 Payment Methodology... 7 Quality Incentive Payout Timeline... 8 Program Terms and Conditions... 8 2019 PCP Global

More information

GLOBAL P4P. Pay for Performance (P4P) Program Guide

GLOBAL P4P. Pay for Performance (P4P) Program Guide GLOBAL P4P Pay for Performance (P4P) Program Guide Contact: QualityPrograms@iehp.org Published: January 10, 2018 PROGRAM OVERVIEW IEHP is pleased to provide an update for the Global Quality Pay for Performance

More information

GLOBAL P4P. Pay for Performance (P4P) Program Guide

GLOBAL P4P. Pay for Performance (P4P) Program Guide GLOBAL P4P Pay for Performance (P4P) Program Guide Contact: QualityPrograms@iehp.org Published: January 8, 2019 TABLE OF CONTENTS Program Overview... 1 Performance Measures... 5 Scoring and Payment Flowchart...

More information

The clinical quality measures as selected by the Clinical Management subcommittee for 2016 for the adult population are:

The clinical quality measures as selected by the Clinical Management subcommittee for 2016 for the adult population are: For 2016 the Clinical Integration Program is moving its clinical quality measures from the Verisk Healthcare Quality and Risk Measures to the National Committee for Quality Assurance HEDIS based measures.

More information

2018 Global Quality IPA Pay For Performance (P4P) Program Guide

2018 Global Quality IPA Pay For Performance (P4P) Program Guide 2018 Global Quality IPA Pay For Performance (P4P) Program Guide Contact: QualityPrograms@iehp.org Published: December 15, 2017 Page 1 Program IEHP is pleased to provide an update for the Global Quality

More information

2018 P4P Overview 0518.PR.P.PP.1 6/18

2018 P4P Overview 0518.PR.P.PP.1 6/18 2018 P4P Overview Agenda MHS Pay For Performance (P4P) Ambetter P4P Program Secure Web Reporting Question and Answer What You Will Learn 1. Measure Overviews & Specifications 2. Documentation Requirements

More information

Quality ID #444 (NQF 1799): Medication Management for People with Asthma National Quality Strategy Domain: Efficiency and Cost Reduction

Quality ID #444 (NQF 1799): Medication Management for People with Asthma National Quality Strategy Domain: Efficiency and Cost Reduction Quality ID #444 (NQF 1799): Medication Management for People with Asthma National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE:

More information

ABCBS PCMH Specifications. ARKANSAS BLUE CROSS and BLUE SHIELD An Independent Licensee of the Blue Cross and Blue Shield Association

ABCBS PCMH Specifications. ARKANSAS BLUE CROSS and BLUE SHIELD An Independent Licensee of the Blue Cross and Blue Shield Association ABCBS PCMH 2016 Specifications An Independent Licensee of the Blue Cross and Blue Shield Association Table of Contents I. Terminology 3 II. Transformation Activities 2016 List of Activities 4 3 month 5-9

More information

SUMMARY TABLE OF MEASURES, PRODUCT LINES AND CHANGES

SUMMARY TABLE OF MEASURES, PRODUCT LINES AND CHANGES Summary Table of Measures, Product Lines and Changes 1 SUMMARY TABLE OF MEASURES, PRODUCT LINES AND CHANGES General Guidelines for Data Collection and Reporting Guidelines for Calculations and Sampling

More information

Clinical Quality Measures Summary of Upcoming Enhancements

Clinical Quality Measures Summary of Upcoming Enhancements Upcoming coding enhancements will impact the logic behind the clinical quality indicators applicable to your practice specialty. Please refer to this grid for a summary of the coding enhancements and some

More information

PCMH 2018 Enrollment and Update August 25, 2017

PCMH 2018 Enrollment and Update August 25, 2017 PCMH 2018 Enrollment and Update August 25, 2017 Enrollment Requirements Anne Santifer HealthCare Innovations Department of Human Services 2018 Enrollment Requirements A physician practice that is enrolled

More information

Medicare STRIDE SM Physician Quality Program 2019 Program Overview

Medicare STRIDE SM Physician Quality Program 2019 Program Overview Medicare STRIDE SM Quality Program 2019 Program Overview Health Services- Managed by Network Medical Management 2019 Program 1 Medicare Advantage Quality Program Program Overview The Plan will support

More information

Fundamentals of Retina Coding

Fundamentals of Retina Coding Fundamentals of Retina Coding Presented by: Joy Woodke, COE, OCS Sunday, April 2, 2017 ASRS Business of Retina Meeting Dallas, TX American Academy of Ophthalmic Executives Financial Disclosure Joy Woodke,

More information

A Partnership in Quality Reporting. Effectiveness of Care: Prevention and Screening

A Partnership in Quality Reporting. Effectiveness of Care: Prevention and Screening A Partnership in Quality Reporting Effectiveness of Care: Prevention and Screening Codes to Identify Well-Child Visits Completed during First 15 Months of Life ICD-9-CM Diagnosis Codes 99381, 99382, 99391,

More information

Advances in Alignment, Measurement, and Performance MY 2017 Results Highlights

Advances in Alignment, Measurement, and Performance MY 2017 Results Highlights Advances in Alignment, Measurement, and Performance MY 2017 Results Highlights Align. Measure. Perform. (AMP) Programs Launched in 2003, VBP4P is a statewide performance improvement program and one of

More information

Blue Cross and Blue Shield of Louisiana 2016 Healthcare Effectiveness Data and Information Set (HEDIS) Coding and Documentation Guide

Blue Cross and Blue Shield of Louisiana 2016 Healthcare Effectiveness Data and Information Set (HEDIS) Coding and Documentation Guide Blue Cross and Blue Shield of Louisiana 2016 Healthcare Effectiveness Data and Information Set (HEDIS) Coding and Documentation Guide Measure Measure Description Protocol or Documentation Required Coding

More information

HEDIS/Quality Assurance Reporting Requirements coding review

HEDIS/Quality Assurance Reporting Requirements coding review HEDIS/Quality Assurance Reporting Requirements coding review Agenda What is HEDIS /Quality Assurance Reporting Review (QARR)? Why is coding important for HEDIS/QARR? Coding focus topics: o Adolescent well

More information

Arkansas Blue Cross and Blue Shield (ABCBS) Patient Centered Medical Home (PCMH) Specifications Manual

Arkansas Blue Cross and Blue Shield (ABCBS) Patient Centered Medical Home (PCMH) Specifications Manual Arkansas Blue Cross and Blue Shield (ABCBS) Patient Centered Medical Home (PCMH) Specifications Manual 2017 This document is a guide to the 2017 Arkansas Blue Cross and Blue Shield Patient-Centered Medical

More information

Quality Corp Measures Description and Methodologies

Quality Corp Measures Description and Methodologies Quality Corp Measures Description and Methodologies Overview: The Oregon Health Care Quality Corporation (Q Corp) is dedicated to improving the quality and affordability of health care in Oregon by leading

More information

Strep Test 87070, 87071, 87081, Pharyngitis (CWP)

Strep Test 87070, 87071, 87081, Pharyngitis (CWP) Clinical Excellence Measures Use of these codes should be appropriate to the service(s) rendered and follow the billing guidelines. For HEDIS measures the codes are from the NCQA HEDIS specifications and

More information

HEDIS Quick Reference Guide Updated to reflect NCQA HEDIS 2016 Technical Specifications

HEDIS Quick Reference Guide Updated to reflect NCQA HEDIS 2016 Technical Specifications HEDIS Quick Reference Guide Updated to reflect NCQA HEDIS 2016 Technical Specifications Fidelis SecureCare strives to provide quality healthcare to our membership as measured through HEDIS quality metrics.

More information

NCC Pediatrics Continuity Clinic Curriculum: Medical Home Module 2 Well Visits

NCC Pediatrics Continuity Clinic Curriculum: Medical Home Module 2 Well Visits NCC Pediatrics Continuity Clinic Curriculum: Medical Home Module 2 Well Visits Overall Goal: To identify strategies for providing comprehensive care during a well visit. The provision of comprehensive

More information

Introduction to HEDIS 2016 Presented by the Quality Improvement Department at Gold Coast Health Plan

Introduction to HEDIS 2016 Presented by the Quality Improvement Department at Gold Coast Health Plan Introduction to HEDIS 2016 Presented by the Quality Improvement Department at Gold Coast Health Plan Ventura County s Medi-Cal Managed Care Plan Serving Ventura County since July 1, 2011 1 Contents I.

More information

Quality Corp Measures Description and Methodologies

Quality Corp Measures Description and Methodologies Quality Corp Measures Description and Methodologies Overview: The Oregon Health Care Quality Corporation (Q Corp) is dedicated to improving the quality and affordability of health care in Oregon by leading

More information

HEDIS 2018 MEASURES. Performance Ratings Operations Department

HEDIS 2018 MEASURES. Performance Ratings Operations Department HEDIS 2018 MEASURES Performance Ratings Operations Department ABA Adult BMI Assessment Members ages 18 74 years of age What makes them compliant? Documentation in the medical record must reflect office

More information

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY Measure #134 (NQF 0418): Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan National Quality Strategy Domain: Community/Population Health 2016 PQRS OPTIONS FOR INDIVIDUAL

More information

2017 Performance Recognition Program PROVIDER INCENTIVE PROGRAM FOR: BCN HMO SM Commercial BCN Advantage SM Blue Cross Medicare Plus Blue SM PPO

2017 Performance Recognition Program PROVIDER INCENTIVE PROGRAM FOR: BCN HMO SM Commercial BCN Advantage SM Blue Cross Medicare Plus Blue SM PPO Confidence comes with every card. 2017 Performance Recognition Program PROVIDER INCENTIVE PROGRAM FOR: BCN HMO SM Commercial BCN Advantage SM Blue Cross Medicare Plus Blue SM PPO Revised October 2017 CONTENTS

More information

NCQA Health Insurance Plan Ratings Methodology October 2014

NCQA Health Insurance Plan Ratings Methodology October 2014 NCQA Health Insurance Plan Ratings Methodology October 2014 REVISION CHART Date Published December 2013 April 2014 October 2014 Description Draft version Final version Updated measure list with 50% rule

More information

STRIDE SM Quality Program 2017 Program Overview

STRIDE SM Quality Program 2017 Program Overview STRIDE SM Quality Program 2017 Program Overview Health Services 2017 Program 1 Quality Program Program Overview The Plan will support the efforts of the LCU and LCU Participating Providers in managing

More information

HEDIS Documentation and Coding Adult Guidelines 2017

HEDIS Documentation and Coding Adult Guidelines 2017 HEDIS Documentation and Coding Adult Guidelines 2017 Reproduced with permission from HEDIS 2017, Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA).

More information

Fee for Service Pay for Performance Program Guidelines Program Year

Fee for Service Pay for Performance Program Guidelines Program Year Fee for Service Pay for Performance Program Guidelines 2018 Program Year 2 General Program Guidelines Table of Contents General Program Guidelines... 4 Program Overview... 4 Provider Participation Eligibility...

More information

December 2018 CTC/OHIC Measure Specifications

December 2018 CTC/OHIC Measure Specifications Overarching Principles and Definitions Active Patients: Patients seen by a primary care clinician of the PCMH anytime within the last 24 months Definition of primary care clinician includes the following:

More information

Changes for Physician Measurement 2018

Changes for Physician Measurement 2018 Changes for Physician Measurement 2018 Measure Name Guidelines for Physician Measurement Effectiveness of Care Changes Revised the Systematic Sampling Methodology to require organizations to report using

More information

SUMMARY TABLE OF MEASURE CHANGES

SUMMARY TABLE OF MEASURE CHANGES Summary Table of Measure 1 SUMMARY TABLE OF MEASURE CHANGES Guidelines for Physician Measurement Adult BMI Assessment Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents

More information

Measure Name: Acute Bronchitis Treatment without Antibiotics Measure Code: BRN Lab Data: N

Measure Name: Acute Bronchitis Treatment without Antibiotics Measure Code: BRN Lab Data: N Measure Name: Acute Bronchitis Treatment without Antibiotics Owner: NCQA (AAB) Measure Code: BRN Lab Data: N Rule Description: Applicable Provider Specialty: General Criteria Summary The percentage of

More information

Trending Determinations by Measure

Trending Determinations by Measure 1100 13th Street NW, Third Floor Washington, DC 20005 phone 202.955.3500 fax 202.955.3599 www.ncqa.org TO: Interested Parties FROM: Cindy Ottone, Director, Policy DATE: March 2019 RE: HEDIS 1 2019 Measure

More information

HEDIS. Quick Reference Guide. For more information, visit

HEDIS. Quick Reference Guide. For more information, visit HEDIS Quick Reference Guide For more information, visit www.ncqa.org HEDIS Quick Reference Guide Updated to reflect NCQA HEDIS 2017 Technical Specifications Michigan Complete Health Medicare-Medicaid Plan

More information

Quality Care Plus 2015 Primary Care Physician Incentive Program. Now includes Medicare patients!

Quality Care Plus 2015 Primary Care Physician Incentive Program. Now includes Medicare patients! Quality Care Plus 2015 Primary Care Physician Incentive Program Now includes Medicare patients! Health Partners Plans (HPP) would like to express our appreciation for the invaluable role our primary care

More information

Commercial Business Medical Cost Target

Commercial Business Medical Cost Target Commercial Business Medical Cost Target Measurement Period Handbook For Enhanced Personal Health Care Measurement Period beginning: April 1, 2018 CBMCT 040118 V3 Introduction Welcome to your Commercial

More information

May 2016 CTC/OHIC Measure Specifications

May 2016 CTC/OHIC Measure Specifications Active Patients: Overarching Principles and Definitions Out patients seen by a primary care clinician of the PCMH anytime within the last 24 months. Definition of primary care clinician includes the following:

More information

Medicare Advantage Measurement Period Handbook for Enhanced Personal Health Care Measurement Period beginning January 1, 2015

Medicare Advantage Measurement Period Handbook for Enhanced Personal Health Care Measurement Period beginning January 1, 2015 Medicare Advantage Measurement Period Handbook for Enhanced Personal Health Care Measurement Period beginning January 1, 2015 Amerivantage is an HMO plan with a contract with the New Mexico Medicare program.

More information

Policy Evaluation: Step Therapy Prior Authorization of Combination Inhaled Corticosteroid / Long-Acting Beta-Agonists

Policy Evaluation: Step Therapy Prior Authorization of Combination Inhaled Corticosteroid / Long-Acting Beta-Agonists Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Policy Evaluation: Step Therapy Prior

More information

Frequently Asked Questions (FAQ) IHA Align. Measure. Perform. (AMP) Programs January Audit Audit Roadmap Posted 1/23/19

Frequently Asked Questions (FAQ) IHA Align. Measure. Perform. (AMP) Programs January Audit Audit Roadmap Posted 1/23/19 Frequently Asked Questions (FAQ) IHA Align. Measure. Perform. (AMP) Programs January 2019 Audit Audit Roadmap Question: For the AMP MY 2018 Roadmap, is the last part of question 5.2W in Section 5, Describe

More information

Care1st Health Plan Taking Quality to the Next Level REPORTING YEAR HEDIS Summary - MPL (Measurement Year 2012)

Care1st Health Plan Taking Quality to the Next Level REPORTING YEAR HEDIS Summary - MPL (Measurement Year 2012) Care1st Health Plan s Quality Improvement Department has been diligently working towards improving the Healthcare Effectiveness Data and Information Sets (HEDIS) results across all lines of business. HEDIS

More information

Multi-Specialty Quality Measure Information Sheet 2017

Multi-Specialty Quality Measure Information Sheet 2017 Prevention and Screening Adolescent Preventive Care Measures (APC) The percentage of adolescents 12-17 years of age who had at least one outpatient visit with a PCP or OB/ GYN practitioner during the measurement

More information

HEDIS. Quick Reference Guide. For more information, visit

HEDIS. Quick Reference Guide. For more information, visit HEDIS Quick Reference Guide For more information, visit www.ncqa.org HEDIS Quick Reference Guide Updated to reflect NCQA HEDIS 2018 Technical Specifications Michigan Complete Health strives to provide

More information

Commercial Business Medical Cost Target

Commercial Business Medical Cost Target Commercial Business Medical Cost Target Measurement Period Handbook For Enhanced Personal Health Care Measurement Period beginning: April 1, 2018 CBMCT 040118 V1 Introduction Welcome to your Commercial

More information

Note: This is an outcome measure and will be calculated solely using registry data.

Note: This is an outcome measure and will be calculated solely using registry data. Measure #384: Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room Within 90 Days of Surgery National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR

More information

2017 HEDIS Measures. PREVENTIVE SCREENING 2017 Measure Quality Indicator

2017 HEDIS Measures. PREVENTIVE SCREENING 2017 Measure Quality Indicator PREVENTIVE SCREENING Childhood Immunization Children who turn 2 during the Adolescent Immunization Adolescents who turn 13 during the Lead Screening Children who turn 2 during the Breast Cancer Screening

More information

Note: This is an outcome measure and will be calculated solely using MIPS eligible clinician, group, or third party intermediary submitted data.

Note: This is an outcome measure and will be calculated solely using MIPS eligible clinician, group, or third party intermediary submitted data. Quality ID #384: Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room Within 90 Days of Surgery National Quality Strategy Domain: Effective Clinical Care Meaningful

More information

Commercial Business Measurement Period Handbook-Medical Cost Target Model For Enhanced Personal Health Care Measurement Period beginning: 01/1/17

Commercial Business Measurement Period Handbook-Medical Cost Target Model For Enhanced Personal Health Care Measurement Period beginning: 01/1/17 Commercial Business Measurement Period Handbook-Medical Cost Target Model For Enhanced Personal Health Care Measurement Period beginning: 01/1/17 CBMCT Version 010117 V3 Introduction: Welcome to your Commercial

More information

PracticePerspectives. Winter. Using Medicare PQRS 2014 Individual Measures in Clinical Practice* Mirean Coleman, LICSW, CT

PracticePerspectives. Winter. Using Medicare PQRS 2014 Individual Measures in Clinical Practice* Mirean Coleman, LICSW, CT I S S U E Winter M A R C H 2 0 1 4 PracticePerspectives The National Association of Social Workers 750 First Street NE Suite 700 Washington, DC 20002-4241 SocialWorkers.org Mirean Coleman, LICSW, CT Senior

More information

2017 Annual Report Healthcare Effectiveness Data and Information Set (HEDIS) Prepared by the Health Plan s Quality Management Department

2017 Annual Report Healthcare Effectiveness Data and Information Set (HEDIS) Prepared by the Health Plan s Quality Management Department 2017 Annual Report Healthcare Effectiveness Data and Information Set (HEDIS) Prepared by the Health Plan s Quality Management Department Table of Contents Executive Summary 3 Introduction 5 Description

More information

04/11/2014. Retina Coding and Reimbursement 101. Financial Disclosure. Chief Complaint

04/11/2014. Retina Coding and Reimbursement 101. Financial Disclosure. Chief Complaint Retina Coding and Reimbursement 101 William T. Koch, COA, COE, CPC Administrative Director Director of Billing Operations The Retina Institute St. Louis, Missouri Advisory Boards Allergan Genentech Regeneron

More information

HEDIS Adult. Documentation and Coding Guidelines Medical record documentation required. Measure description. Coding ICD-10: Z68.1 Z68.45, Z68.

HEDIS Adult. Documentation and Coding Guidelines Medical record documentation required. Measure description. Coding ICD-10: Z68.1 Z68.45, Z68. HEDIS Adult Documentation and Guidelines 2017 description Adult BMI Assessment (ABI) Members 18 74 years of age who had an outpatient visit and whose body mass index (BMI) was documented during the measurement

More information

Exhibit I-1 Performance Measures. Numerator (general description only)

Exhibit I-1 Performance Measures. Numerator (general description only) # Priority Type Performance Measure Core Measures (implement 9/1/09) 1 C OE Hospital readmissions within 7, 30 and 90 days postdischarge 2 C OE Percent of Members prescribed redundant or duplicated antipsychotic

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #134 (NQF 0418): Preventive Care and Screening: Screening for Depression and Follow-Up Plan National Quality Strategy Domain: Community/Population Health 2018 OPTIONS FOR INDIVIDUAL MEASURES:

More information

HEDIS Documentation & Coding Guidelines 2015

HEDIS Documentation & Coding Guidelines 2015 Effectiveness of Care: Prevention & Screening Members 18 74 years of age who had an outpatient visit and BMI ICD-9: V85.0 - V85.45 whose body mass index (BMI) was documented during the measurement year

More information

2017 Diabetes. Program Evaluation. Our mission is to improve the health and quality of life of our members

2017 Diabetes. Program Evaluation. Our mission is to improve the health and quality of life of our members 2017 Diabetes Program Evaluation Our mission is to improve the health and quality of life of our members Diabetes Program Evaluation Program Title: Diabetes Program Evaluation Period: January 1, 2017 December

More information

Greater Financial Rewards: IEHP s 2017 Global P4P Program

Greater Financial Rewards: IEHP s 2017 Global P4P Program Volume 6 Fall 017 Greater Financial Rewards: IEHP s 017 Global PP Program Financial Overview IEHP is pleased to announce the 017 Global Quality PP (GQ PP) Program for Medi-Cal IPAs and PCPs. An expansion

More information

MEASURING CARE QUALITY

MEASURING CARE QUALITY MEASURING CARE QUALITY Region December 2013 For Clinical Effectiveness of Care Measures of Performance From: Healthcare Effectiveness Data and Information Set (HEDIS ) HEDIS is a set of standardized performance

More information

HEDIS/CAHPS 101 August 13, 2012 Minnesota Measurement and Reporting Workgroup

HEDIS/CAHPS 101 August 13, 2012 Minnesota Measurement and Reporting Workgroup HEDIS/CAHPS 101 Minnesota Measurement and Reporting Workgroup MNsure s Accessibility & Equal Opportunity (AEO) office can provide this information in accessible formats for individuals with disabilities.

More information

04/06/2015. Documentation Do s and Don ts In The Retina Practice. Financial Disclosure. Documentation Dos and Don ts

04/06/2015. Documentation Do s and Don ts In The Retina Practice. Financial Disclosure. Documentation Dos and Don ts Documentation Do s and Don ts In The Retina Practice William T. Koch, COA, COE, CPC Administrative Director Director of Billing Operations The Retina Institute St. Louis, Missouri Advisory Boards Allergan

More information

PracticePerspectives. Winter. Using Medicare PQRS 2014 Individual Measures in Clinical Practice* Mirean Coleman, LICSW, CT

PracticePerspectives. Winter. Using Medicare PQRS 2014 Individual Measures in Clinical Practice* Mirean Coleman, LICSW, CT I S S U E Winter M A R C H 2 0 1 4 PracticePerspectives The National Association of Social Workers 750 First Street NE Suite 700 Washington, DC 20002-4241 SocialWorkers.org Mirean Coleman, LICSW, CT Senior

More information

Combining Risk Adjustment and HEDIS to Improve Quality of Care. Colleen Gianatasio, CPC, CPC-P, CPMA, CPC-I, CRC

Combining Risk Adjustment and HEDIS to Improve Quality of Care. Colleen Gianatasio, CPC, CPC-P, CPMA, CPC-I, CRC Combining Risk Adjustment and HEDIS to Improve Quality of Care Colleen Gianatasio, CPC, CPC-P, CPMA, CPC-I, CRC Agenda Improving primary care in today s health care environment Risk adjustment basics (using

More information

2018 Commercial HMO/POS HEDIS 1 Results

2018 Commercial HMO/POS HEDIS 1 Results 08 Commercial HMO/POS HEDIS Results Weight Assessment & Counseling for Nutrition & Physical Activity for Children/Adolescents HEDIS 06 CY 05 HEDIS 07 CY 06 HEDIS 08 CY 07 Compass BMI Percentile 70.47%

More information

Adult-Peds Quality Measure Information Sheet 2018

Adult-Peds Quality Measure Information Sheet 2018 Prevention and Screening Adolescent Preventive Care Measures (ADL) The percentage of adolescents 12-17 years of age who had at least one outpatient visit with a PCP or OB/ GYN practitioner during the measurement

More information

Commercial Business Measurement Period Handbook For Patient-Centered Primary Care

Commercial Business Measurement Period Handbook For Patient-Centered Primary Care Commercial Business Measurement Period Handbook For Patient-Centered Primary Care Measurement Period beginning: 07/01/16 CB Version 070116 V1 Introduction: Welcome to your Commercial Business Measurement

More information

Preferred Care Partners. HEDIS Technical Standards

Preferred Care Partners. HEDIS Technical Standards Preferred Care Partners HEDIS Technical Standards 1 HEDIS What is HEDIS HEDIS Overview Adults HEDIS Overview Pediatrics HEDIS is a registered trademark of the National Committee for Quality Assurance 2

More information

MEASURING CARE QUALITY

MEASURING CARE QUALITY MEASURING CARE QUALITY Region November 2016 For Clinical Effectiveness of Care Measures of Performance From: Healthcare Effectiveness Data and Information Set (HEDIS ) HEDIS is a set of standardized performance

More information

Quality Program Measures

Quality Program Measures QUALITY Quality Program s BLUECARE TENNESSEE Thank you for your participation in BlueCare Quality Improvement. With your help, we can improve the care and health outcomes for our members. This guide includes

More information

and at the same patient encounter. Code has been deleted. For scanning computerized ophthalmic diagnostic imaging of optic nerve and retin

and at the same patient encounter. Code has been deleted. For scanning computerized ophthalmic diagnostic imaging of optic nerve and retin 92227: Remote imaging for detection of retinal disease (eg, retinopathy in a patient with diabetes) with analysis and report under physician supervision, unilateral or bilateral. For Medicare, bill only

More information

COMMUNITY HEALTH GROUP HEDIS MEASURES (CY 2012) MEDICARE QUICK REFERENCE GUIDE FOR BILLING DEPARTMENT

COMMUNITY HEALTH GROUP HEDIS MEASURES (CY 2012) MEDICARE QUICK REFERENCE GUIDE FOR BILLING DEPARTMENT HEDIS MEASURES (CY ) MEDICARE QUICK REFERENCE GUIDE FOR BILLING DEPARTMENT Care for Older Adults Colorectal Cancer Screening Annual Monitoring for Patients on Persistent Medications COA COL MPM Age Description

More information

IHA P4P Measure Manual Measure Year Reporting Year 2018

IHA P4P Measure Manual Measure Year Reporting Year 2018 ADULT PREVENTIVE CARE IHA P4P Measure Manual Measure Year 2017 - Reporting Year 2018 *If line of business not labeled, measure is Commercial only Adult BMI (Medicare) 18-74 Medicare members ages 18-74

More information

Blue Cross Complete of Michigan Performance Recognition Program Incentive Materials 2017

Blue Cross Complete of Michigan Performance Recognition Program Incentive Materials 2017 Performance Recognition Program Incentive Materials 2017 Blue Cross Complete of Michigan 2017 Performance Recognition Program Dear Blue Cross Complete of Michigan-affiliated primary care physician or group

More information

2017 MSSP Clinical Quality Measures

2017 MSSP Clinical Quality Measures *The information contained in this document relies heavily on information supplied by CMS. GPRO CARE-1 (NQF 0097): Medication Reconciliation Post-Discharge DESCRIPTION: Percentage of discharges from any

More information

Texas Vendor Drug Program Specialty Drug List Process. February 2019

Texas Vendor Drug Program Specialty Drug List Process. February 2019 Texas Vendor Drug Program Specialty Drug List Process February 2019 Table of Contents Table of Contents...1 1 About the Specialty Drug List...2 1.1 Information for Pharmacies... 2 1.2 Information for Managed

More information

Patient sample criteria for the Preventive Care Measure Group are patients aged 50 years and older with a specific patient encounter:

Patient sample criteria for the Preventive Care Measure Group are patients aged 50 years and older with a specific patient encounter: 2016 Physician Quality Reporting System Data Collection Form: Preventive Care (for patients aged 50 and older) NOTE: Individual measures may have more restrictive age and gender requirements. IMPORTANT:

More information

Healthcare Effectiveness Data and Information Set Quality Assurance Reporting Requirements

Healthcare Effectiveness Data and Information Set Quality Assurance Reporting Requirements HEDIS/QARR Healthcare Effectiveness Data and Information Set Quality Assurance Reporting Requirements 2015 Quick Reference Guide ADULTS Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis

More information

B&T Format. New Measures. Better health care. Better choices. Better health.

B&T Format. New Measures. Better health care. Better choices. Better health. 1100 13th Street NW, Third Floor Washington, DC 20005 phone 202.955.3500 fax 202.955.3599 www.ncqa.org TO: Interested Organizations FROM: Patrick Dahill, Assistant Vice President, Policy DATE: February

More information

QBPC Claims Based Provider Quick Reference Guide

QBPC Claims Based Provider Quick Reference Guide QBPC Claims Based Provider Quick Reference Guide Category: Diabetes Chronic Suite ICD-10-CM diagnosis HbA1c Test Codes LOINC Evidence of Treatment for Nephropathy Codes E10; E11; E13 83036-37 17856-6,

More information

HEDIS QUICK REFERENCE GUIDE: DOCUMENTATION TIPS FOR ADULT MEASURES

HEDIS QUICK REFERENCE GUIDE: DOCUMENTATION TIPS FOR ADULT MEASURES HEDIS QUICK REFERENCE GUIDE: DOCUMENTATION TIPS FOR ADULT MEASURES For Health Care Providers January 2018 Helping you improve your scores, as you improve the health of your patients. Healthcare Effectiveness

More information

Quality ID #117 (NQF 0055): Diabetes: Eye Exam National Quality Strategy Domain: Effective Clinical Care

Quality ID #117 (NQF 0055): Diabetes: Eye Exam National Quality Strategy Domain: Effective Clinical Care Quality ID #117 (NQF 0055): Diabetes: Eye Exam National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: Percentage

More information

FAMILY MEDICINE PRACTICES

FAMILY MEDICINE PRACTICES 2018 Primary Care Provider Quality Improvement Program (PCP QIP) Measurement Specifications FAMILY MEDICINE PRACTICES Developed by: The QIP Team QIP@partnershiphp.org Published: November 28, 2017 Updated:

More information

Evidence Based Care Report (EBCR) Measure Specifications for PGIP 2011 Program Year

Evidence Based Care Report (EBCR) Measure Specifications for PGIP 2011 Program Year Evidence Based Care Report (EBCR) Measure Specifications for PGIP 2011 Program Year Source: BCBSM PGIP Program Released: This page is an overview of changes to the EBCR measures for the 2011 Program Year.

More information

Progressive Symptomatic Retinal Detachment Complicating Retinoschisis. Initial Reporting Questionnaire

Progressive Symptomatic Retinal Detachment Complicating Retinoschisis. Initial Reporting Questionnaire Progressive Symptomatic Retinal Detachment Complicating Retinoschisis In association with the British Ophthalmological Surveillance Unit Ethics ref: 13/NW/0037 Initial Reporting Questionnaire Case Definition:

More information

Performance Improvement Projects Related to CDC s 6 18 Initiative: A Scan of External Quality Review Organization Reports

Performance Improvement Projects Related to CDC s 6 18 Initiative: A Scan of External Quality Review Organization Reports Technical Assistance Tool June 2018 Performance Improvement Projects Related to CDC s 6 18 Initiative: A Scan of External Quality Review Organization Reports S tates implementing interventions under CDC

More information

INTERNAL MEDICINE PRACTICES

INTERNAL MEDICINE PRACTICES 2018 Primary Care Provider Quality Improvement Program (PCP QIP) Measurement Specifications INTERNAL MEDICINE PRACTICES Developed by: The QIP Team QIP@partnershiphp.org Published: November 28, 2017 Updated:

More information

Colorado State Innovation Model (SIM) Clinical Quality Measures (CQMs) Reporting Schedules

Colorado State Innovation Model (SIM) Clinical Quality Measures (CQMs) Reporting Schedules Colorado State Innovation Model (SIM) Clinical Quality Measures (CQMs) Reporting Schedules 1 SIM Clinical Quality Measure (CQM) Reporting Schedules: Cohort 3 Table of Contents Reporting Schedules... 3

More information

Quality measures desktop reference for Medicaid providers

Quality measures desktop reference for Medicaid providers Quality measures desktop reference for Medicaid providers providers.amerigroup.com Please note: The information provided is based on 2016 technical specifications and is subject to change based on guidance

More information

QIP/HEDIS Measure Webinar Series

QIP/HEDIS Measure Webinar Series QIP/HEDIS Measure Webinar Series September 26, 2017 Presenters: Partnership HealthPlan Quality Department Partnership HealthPlan of California To avoid echoes and feedback, we request that you use the

More information

Quality measures desktop reference for Medicaid providers

Quality measures desktop reference for Medicaid providers Quality measures desktop reference for Medicaid providers providers.amerigroup.com Please note: The information provided is based on 2016 technical specifications and is subject to change based on guidance

More information

Medicare Shared Savings Program Quality Measure Benchmarks for the 2014 and 2015 Reporting Years

Medicare Shared Savings Program Quality Measure Benchmarks for the 2014 and 2015 Reporting Years Medicare Shared Savings Program Quality Measure Benchmarks for the 2014 and 2015 Reporting Years Introduction This document describes methods for calculating the quality performance benchmarks for Accountable

More information

Florida Blue QUALITY PERFORMANCE METRIC STANDARDS FEBRUARY 2013

Florida Blue QUALITY PERFORMANCE METRIC STANDARDS FEBRUARY 2013 Florida Blue QUALITY PERFORMANCE METRIC STANDARDS FEBRUARY 2013 QUALITY PERFORMANCE METRIC CALCULATION QUALITY METRICS SELECTED FOR MEASUREMENT Per Section 3.2 of the Agreement, HCPP must meet the following

More information

2017 Medicare STARs Provider Quality Indicators Guide

2017 Medicare STARs Provider Quality Indicators Guide 2017 Medicare STARs Provider Quality Indicators Guide Medicare STARs Rating Centers for Medicare & Medicaid Services (CMS) created a Five-Star Quality Rating System to help measure the quality in care

More information

Value Based Pay for Performance Results & Highlights Measurement Year September 2017

Value Based Pay for Performance Results & Highlights Measurement Year September 2017 Value Based Pay for Performance Results & Highlights Measurement Year 2016 September 2017 IHA s Value Based Pay for Performance (VBP4P) ~200 Medical Groups & IPAs 9 Health Plans Common Measurement Public

More information